<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Quetiapine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Quetiapine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Quetiapine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11010" href="/d/html/11010.html" rel="external">see "Quetiapine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="89427" href="/d/html/89427.html" rel="external">see "Quetiapine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709379"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Quetiapine is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behavior:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients older than 24 years; there was a reduction in risk with antidepressant use in patients 65 years and older. In patients of all ages who are started on antidepressant therapy, monitor closely for clinical worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Quetiapine is not approved for use in pediatric patients younger than 10 years.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F216269"><span class="drugH1">Brand Names: US</span>
<ul>
<li>SEROquel;</li>
<li>SEROquel XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868088"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Quetiapine Fumarate XR;</li>
<li>ACT QUEtiapine;</li>
<li>AG-Quetiapine;</li>
<li>AG-Quetiapine Fumarate;</li>
<li>AG-Quetiapine XR;</li>
<li>APO-QUEtiapine;</li>
<li>APO-Quetiapine Fumarate;</li>
<li>APO-QUEtiapine XR;</li>
<li>Auro-QUEtiapine;</li>
<li>BIO-QUEtiapine;</li>
<li>DOM-QUEtiapine;</li>
<li>JAMP-QUEtiapine;</li>
<li>JAMP-Quetiapine Fumarate;</li>
<li>M-Quetiapine Fumarate XR;</li>
<li>Mar-QUEtiapine [DSC];</li>
<li>MINT-QUEtiapine;</li>
<li>MINT-Quetiapine XR;</li>
<li>NAT-QUEtiapine;</li>
<li>NRA-Quetiapine;</li>
<li>NRA-Quetiapine XR;</li>
<li>PMS-QUEtiapine;</li>
<li>Priva-QUEtiapine [DSC];</li>
<li>PRO-QUEtiapine;</li>
<li>RAN-QUEtiapine;</li>
<li>RIVA-QUEtiapine;</li>
<li>SANDOZ QUEtiapine XRT;</li>
<li>SANDOZ QUEtiapine [DSC];</li>
<li>SEROquel;</li>
<li>SEROquel XR;</li>
<li>TARO-Quetiapine;</li>
<li>TEVA-QUEtiapine XR;</li>
<li>TEVA-QUEtiapine [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F216298"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimanic Agent;</li>
<li>
                        Second Generation (Atypical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F216274"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b86ae9af-0983-405b-8c0b-a20590d54c4c">Agitation/Aggression and psychosis associated with dementia, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression and psychosis associated with dementia, severe or refractory (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For short-term adjunctive use while addressing underlying cause(s) of severe symptoms. In patients without a clinically significant response after an adequate trial (eg, up to 4 weeks), taper and withdraw therapy. Only continue in patients with demonstrated benefit; attempt to taper and withdraw at regular intervals (eg, within 4 months of initiation). Patients with dementia with Lewy bodies are at increased risk for severe adverse reactions; caution is required even with low doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 25 mg at bedtime; may increase dose gradually (eg, weekly) based on response and tolerability up to 75 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Press.2019','lexi-content-ref-12040309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Press.2019','lexi-content-ref-12040309'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="461aa12f-7c9f-45cf-9af4-7b96a7680bcf">Agitation and/or delirium, ICU</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation and/or delirium, ICU (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Nonpharmacologic interventions and treatment of underlying conditions are initial steps to prevent and manage delirium. Antipsychotics may be used as short-term adjunctive treatment if distressing symptoms (eg, agitation, anxiety) are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral or via NG tube:</b> Initial: 50 mg twice daily; may increase based on response and tolerability in 100 mg increments at intervals ≥1 day up to a maximum dose of 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19915454','lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19915454','lexi-content-ref-30113379'])">Ref</a></span>). In patients who may be more sensitive to adverse effects, some experts start at 12.5 mg twice daily or 25 to 50 mg at bedtime and increase dose more gradually (eg, in increments of 25 mg/day) based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tietze.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tietze.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute mania (labeled use), acute episodes with mixed features (labeled use [extended release]; off-label use [immediate release]), and acute hypomania (off-label use) (monotherapy or adjunct to antimanic therapy):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 100 to 200 mg once daily at bedtime or in 2 divided doses on day 1, then increase by 100 mg/day (divided twice daily or as single dose at bedtime) until 400 mg/day is reached by day 4; thereafter, may further increase based on response and tolerability in increments of ≤200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16192842','lexi-content-ref-Stovall.2018','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16192842','lexi-content-ref-Stovall.2018','lexi-content-ref-Manu.1'])">Ref</a></span>). Maximum dose: 800 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); however, some patients may require doses up to 1.2 g/day for optimal response, according to some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> Initial: 300 mg once daily on day 1; increase to 600 mg once daily on day 2, then adjust dose based on response and tolerability. Maximum dose: 800 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); however, some patients may require doses up to 1.2 g/day for optimal response, according to some experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bipolar major depression (monotherapy [labeled use] or in combination with antimanic therapy [off-label use]):</i> Immediate release, Extended release: <b>Oral:</b> Initial: 50 mg once daily at bedtime; increase to 100 mg once daily on day 2, further increase by 50 to 100 mg/day to reach a usual target dose of 300 mg once daily by day 4 to 7; maximum dose: 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shelton.2019','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shelton.2019','lexi-content-ref-Manu.1'])">Ref</a></span>). Although increased efficacy with doses &gt;300 mg/day has not been demonstrated in clinical trials, based upon clinical experience, individual patients may require doses up to 800 mg/day for optimal response. If doses &gt;300 mg/day are required, the IR formulation may require 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shelton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shelton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance treatment (monotherapy [off-label use] or adjunct to antimanic therapy [labeled use]):</i> Immediate release, Extended release: <b>Oral:</b> Continue dose and combination regimen that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616'])">Ref</a></span>). Maximum dose: 800 mg/day; however, for patients who required doses up to 1.2 g/day to achieve remission, this dose is initially continued for maintenance treatment if it is tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7834615-81b5-448d-be0f-b6021963e20a">Delusional infestation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional infestation (delusional parasitosis) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 12.5 to 50 mg at bedtime; gradually increase dose based on response and tolerability every 3 to 7 days up to 200 to 300 mg at bedtime or in 2 to 3 divided doses. Continue treatment for at least 3 months before attempting to decrease dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16282853','lexi-content-ref-18794644','lexi-content-ref-23789596','lexi-content-ref-18836354','lexi-content-ref-Suh.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16282853','lexi-content-ref-18794644','lexi-content-ref-23789596','lexi-content-ref-18836354','lexi-content-ref-Suh.2018'])">Ref</a></span>). Some experts suggest targeting a dose of 200 mg/day and would consider discontinuation as soon as 1 month after response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Suh.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Suh.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (monotherapy or adjunct to antidepressants)</b>
<b>(alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Note:</b> Late-line option in refractory generalized anxiety disorder, preferably use in a specialist setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25081580','lexi-content-ref-22540422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25081580','lexi-content-ref-22540422'])">Ref</a></span>). May be used for monotherapy in patients who have not responded to or do not tolerate antidepressants and other first-line agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25081580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25081580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release, Extended release: <b>Oral:</b> Initial: 25 mg once daily (immediate release only) to 50 mg once daily; may gradually increase dose based on response and tolerability every ≥7 days to a usual dosage range of 50 to 200 mg/day in 1 to 3 divided doses based on chosen formulation; maximum recommended dose: 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21403524','lexi-content-ref-Craske.2019','lexi-content-ref-15816805','lexi-content-ref-20881846','lexi-content-ref-24199224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21403524','lexi-content-ref-Craske.2019','lexi-content-ref-15816805','lexi-content-ref-20881846','lexi-content-ref-24199224'])">Ref</a></span>). Immediate release is dosed 1 to 3 times daily; 24-hour extended release is dosed once daily. For the ER tablet, increasing the dose to 100 or 150 mg on day 3 or 4 of therapy may be appropriate for patients with severe symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24199224','lexi-content-ref-23070803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24199224','lexi-content-ref-23070803'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpsychotic depression as adjunct for insufficient response to antidepressants (labeled use [extended release]; off-label use [immediate release]) <b>or</b> psychotic depression in combination with an antidepressant (off-label use): </i>Immediate release, Extended release: <b>Oral:</b> Initial: 50 mg/day on days 1 and 2; increase on day 3 to 150 mg/day in 1 to 3 divided doses based on chosen formulation. Immediate release is dosed 1 to 3 times daily; 24-hour extended release is dosed once daily. Usual dosage range: 150 to 300 mg/day in 1 to 3 divided doses based on chosen formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.2018','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.2018','lexi-content-ref-Manu.1'])">Ref</a></span>); however, doses up to 600 mg/day in psychotic depression may be needed and tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19694628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19694628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpsychotic depression, monotherapy (alternative agent) (off-label use):</i> Immediate release, Extended release: <b>Oral:</b> Initial: 50 mg once daily; may gradually increase up to 300 mg/day in 1 to 3 divided doses based on chosen formulation based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23017200','lexi-content-ref-23485955','lexi-content-ref-Thase.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23017200','lexi-content-ref-23485955','lexi-content-ref-Thase.2018'])">Ref</a></span>). Immediate release is dosed 1 to 3 times daily; 24-hour extended release is dosed once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59e68a42-338e-45a3-bae2-8825f8f2f70d">Obsessive-compulsive disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder, treatment resistant (augmentation to antidepressants) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 25 to 50 mg once daily; increase dose gradually based on response and tolerability in increments of 25 to 100 mg every 2 to 3 weeks up to 400 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11981352','lexi-content-ref-15323587','lexi-content-ref-15933483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11981352','lexi-content-ref-15323587','lexi-content-ref-15933483'])">Ref</a></span>). Immediate release is dosed 1 to 3 times daily; 24-hour extended release is dosed once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (adjunct to antidepressants or monotherapy) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 25 mg once daily at bedtime; increase dose in 25 mg increments every 1 to 2 days up to 100 mg at bedtime by the end of week 1; may further adjust dose based on response and tolerability in increments of 25 mg/day, up to 100 mg/week. Average dose in clinical trials: 100 to 336 mg/day (range: 25 to 800 mg/day in 1 to 3 divided doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16317314','lexi-content-ref-12544370','lexi-content-ref-16945162','lexi-content-ref-27418378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16317314','lexi-content-ref-12544370','lexi-content-ref-16945162','lexi-content-ref-27418378'])">Ref</a></span>). Some experts suggest gradually increasing dose based on response and tolerability in increments of 50 mg/week up to a total daily dose of 400 mg in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80d7a391-587d-4c94-81dc-51417f4dba54">Psychosis in Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psychosis in Parkinson disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 12.5 to 25 mg at bedtime; increase dose gradually based on response and tolerability in increments of 12.5 to 25 mg every 1 to 2 weeks; average dose in studies ranged from 40 to 185 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10348474','lexi-content-ref-15090935','lexi-content-ref-17095896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10348474','lexi-content-ref-15090935','lexi-content-ref-17095896'])">Ref</a></span>). Some experts gradually increase dose based on response and tolerability up to 100 mg at bedtime and then add a morning dose if needed to control symptoms, up to a maximum of 200 mg/day as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tarsy.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tarsy.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> Initial: 25 mg twice daily; increase in increments of 25 to 50 mg/day in 2 or 3 divided doses on days 2 and 3 and increase further to a target dose of 300 to 400 mg/day by day 4. May further adjust dose based on response and tolerability in increments of 50 to 100 mg/day every ≥2 days. Acute therapy usual dosage range: 150 to 750 mg/day in 1 to 3 divided doses. Maintenance therapy usual dosage range: 400 to 800 mg/day in 1 to 3 divided doses; maximum dose: 800 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Initial: 300 mg once daily; may increase dose based on response and tolerability in increments of up to 300 mg/day every ≥1 day. Usual dosage range: 400 to 800 mg once daily; maximum dose: 800 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Doses up to 1.6 g/day have been evaluated in clinical studies; however, doses &gt;800 mg/day were not found to offer greater efficacy, may result in greater adverse effects, and are generally <b>not</b> recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21733490','lexi-content-ref-21346616','lexi-content-ref-24945332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21733490','lexi-content-ref-21346616','lexi-content-ref-24945332'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Dosing conversion:</b></i> To convert patients between immediate-release and ER tablets, administer the equivalent total daily dose. Administer immediate-release daily dose in 1 to 3 divided doses and extended release once daily; individual dosage adjustments may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Reinitiation of treatment:</b></i> Patients who have discontinued therapy for &gt;1 week should generally be re-titrated using the initial dosing schedule; patients who have discontinued &lt;1 week can generally be reinitiated on their previous maintenance dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Dosage adjustment for concomitant therapy: </b></i>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy:</i></b> In the treatment of chronic psychiatric disease switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Switching antipsychotics:</i></b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p></div>
<div class="block dora drugH1Div" id="F50990829"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10958148','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10958148','lexi-content-ref-Manu.1'])">Ref</a></span>). Removal by dialysis unlikely due to relatively high protein binding and large volume of distribution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988045"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team<i>: </i>Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Manufacturer recommendations do not specify the level of liver insufficiency associated with dosing recommendations. Pharmacokinetic data are limited to a single dose study performed in 8 patients with unspecified (eg, no Child-Turcotte-Pugh designation) liver insufficiency; AUC, C<sub>max</sub>, and V<sub>d</sub> were substantially higher and clearance impaired compared to healthy controls. Notably, patients with ascites, encephalopathy, or liver transaminases &gt;3 ULN were excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10958148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10958148'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial or dose titration in patients with preexisting liver cirrhosis: </i></b>
<b>Note:</b> Although quetiapine-induced liver injury is rare, changes in liver biochemistries are common; therefore, liver biochemistries should be obtained at baseline, then at 6 weeks and every 3 months during the first year of therapy, then annually thereafter or when clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class A and B:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release: Oral:</b> Initial: 25 mg once daily; may increase by 25 to 50 mg/day based on response and tolerability until effective dose achieved, dividing total daily dose into 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36587739','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36587739','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Extended release: </b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Extended release should not be used for initial dosing in patients with cirrhosis who are quetiapine naive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral: </b>Initial: 50 mg once daily; increase dose by 50 mg once daily until effective dose achieved based on individual clinical response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class C: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36587739','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36587739','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to new Child-Turcotte-Pugh class A through C:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release, extended release:</b> Assess for quetiapine-induced liver injury, and if suspected, discontinue quetiapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017','lexi-content-ref-Expert.DOH'])">Ref</a></span>). If quetiapine-induced hepatoxicity has been ruled out, may continue quetiapine therapy; use the lowest effective dose; consider dose reduction or interruption in therapy for new or worsening somnolence and/or hepatic encephalopathy in collaboration with an appropriate specialist (eg, psychiatrist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12418358','lexi-content-ref-10958148','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12418358','lexi-content-ref-10958148','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening hepatic function (eg, requiring hospitalization):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A through C:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release, extended release:</b> Assess for quetiapine-induced liver injury, and if suspected, discontinue quetiapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36180017','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36180017','lexi-content-ref-Expert.DOH'])">Ref</a></span>). If quetiapine-induced hepatoxicity has been ruled out, may continue quetiapine therapy; use the lowest effective dose; consider dose reduction or interruption in therapy for new or worsening somnolence and/or hepatic encephalopathy in collaboration with an appropriate specialist (eg, psychiatrist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12418358','lexi-content-ref-10958148','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12418358','lexi-content-ref-10958148','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F216275"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose. Of note, use in certain indications (eg, schizophrenia, bipolar disorder) may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder or schizophrenia:</b> Immediate release, Extended release: <b>Oral:</b> Initial: 50 mg/day; may increase based on response and tolerability in increments of 50 mg/day to an effective dose, dividing total daily dose into 1 to 3 divided doses. Immediate release is dosed 1 to 3 times daily; 24-hour extended release is dosed once daily. Some experts recommend starting doses as low as 12.5 to 25 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sajatovic.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sajatovic.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b>
<i>Adjunct to antidepressants or monotherapy (off-label):</i> Extended release: <b>Oral:</b> Initial: 50 mg once daily; may increase by 50 mg/day to an effective dose, based on individual response and tolerability. Maximum dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>): 300 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing for additional uses. Dosages in the lower range of recommended adult dosing are generally sufficient with late-onset schizophrenia or psychosis. Titrate dosage slowly and monitor carefully (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10671383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10671383'])">Ref</a></span>). Reserve for late-line use for anxiety disorders due to tolerability issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35900161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Dosing conversion:</i></b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Reinitiation of treatment:</i></b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage adjustment for concomitant therapy:</i></b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching antipsychotics:</b></i> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F216286"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="89427" href="/d/html/89427.html" rel="external">see "Quetiapine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5507a0a1-e9ef-4242-9941-7f18bb03b959">Bipolar disorder, mania or episodes with mixed features</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder, mania or episodes with mixed features: Note:</b> Due to decreased risk of extrapyramidal symptoms, second-generation antipsychotics including quetiapine have replaced first-generation antipsychotics for treatment as monotherapy or in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-29536616','lexi-content-ref-26237252','lexi-content-ref-NICE.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-29536616','lexi-content-ref-26237252','lexi-content-ref-NICE.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate-release tablet: Oral: Initial: 25 mg twice daily on day 1; increase to 50 mg twice daily on day 2, then 100 mg twice daily on day 3, then 150 mg twice daily on day 4, then continue at the target dose of 200 mg twice daily beginning on day 5. May increase further based on clinical response and tolerability at increments ≤100 mg/day up to 300 mg twice daily; however, no additional benefit was seen with 300 mg twice daily versus 200 mg twice daily. Usual dosage range: 200 to 300 mg twice daily; maximum daily dose: 600 mg/<b>day</b>. Total daily doses may also be divided into 3 doses per day. Continue therapy at lowest dose needed to maintain remission; periodically assess maintenance treatment needs.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended-release tablet: Oral: Initial: 50 mg once daily on day 1; increase to 100 mg once daily on day 2, then increase in 100 mg/day increments each day until a target dose of 400 mg once daily is reached on day 5. Usual dosage range: 400 to 600 mg once daily; maximum daily dose: 600 mg/<b>day</b>; continue therapy at lowest dose needed to maintain remission; periodically assess maintenance treatment needs.</p>
<p style="text-indent:-2em;margin-left:6em;">Switching from immediate release to extended release: May convert patients from immediate-release to extended-release tablets at the equivalent total daily dose and administer once daily; individual dosage adjustments may be necessary.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fbb1b986-c9fc-4768-82c7-58194c01e67e">Delirium; ICU-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium; ICU-associated:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34745700','lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34745700','lexi-content-ref-35119438'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Data in infants is very limited; use with caution; discontinue with taper as soon as possible; pharmacokinetics, safety (QT prolongation), and long-term effects of dopamine-receptor antagonism in this population are not defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26908691','lexi-content-ref-13679531']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26908691','lexi-content-ref-13679531'])">Ref</a></span>). In all pediatric patients, due to risk of QT prolongation, EKG monitoring has been reported at baseline and at 48 hours after therapy initiation; more frequent monitoring may be needed in patients with concomitant therapy that prolongs QT or additional clinical factors.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;2 months, Children, and Adolescents: Immediate release: Oral: Initial: 0.5 mg/kg/dose every 8 to 12 hours; maximum reported initial daily dose: 50 mg/<b>day</b> in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33634425','lexi-content-ref-26908706','lexi-content-ref-35933475','lexi-content-ref-31214433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33634425','lexi-content-ref-26908706','lexi-content-ref-35933475','lexi-content-ref-31214433'])">Ref</a></span>); may titrate by 0.5 mg/kg/dose based on response by routine assessment with a validated screening tool (eg, Cornell Assessment of Pediatric Delirium [CAPD], pediatric Confusion Assessment Method [pCAM], preschool Confusion Assessment Method [psCAM]) up to reported maximum daily dose of 6 mg/kg/<b>day</b> or 200 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33634425','lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33634425','lexi-content-ref-35119438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosage based on small trials and case-series that reported improvement in delirium symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31214433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31214433'])">Ref</a></span>) and significant reductions in concomitant opioid and benzodiazepine dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35933475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35933475'])">Ref</a></span>); however, a small trial did not show improvement in CAPD scores. Reported (if available) duration of therapy was variable (reported median range: 10 to 29 days); quetiapine should be discontinued by tapering dose; do not stop drug abruptly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26908706','lexi-content-ref-31214433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26908706','lexi-content-ref-31214433'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia: Note:</b> Second-generation antipsychotics (including quetiapine) are generally the preferred initial treatment in management of pediatric patients with schizophrenia due to decreased risk of extrapyramidal symptoms and tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23972700','lexi-content-ref-26065063','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23972700','lexi-content-ref-26065063','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate-release tablet: Oral: Initial: 25 mg twice daily on day 1; increase to 50 mg twice daily on day 2, then 100 mg twice daily on day 3, then 150 mg twice daily on day 4, then continue at a target dose of 200 mg twice daily beginning on day 5. May increase further based on clinical response and tolerability at increments ≤100 mg/day up to 400 mg twice daily; however, no additional benefit was seen with 400 mg twice daily versus 200 mg twice daily. Usual dosage range: 200 to 400 mg twice daily; maximum daily dose: 800 mg/<b>day</b>. Total daily doses may also be divided into 3 doses per day. Periodically assess maintenance treatment needs.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended-release tablet: Oral: Initial: 50 mg once daily on day 1; increase to 100 mg once daily on day 2, then increase in 100 mg/day increments each day until a target dose of 400 mg once daily is reached on day 5. Usual dosage range: 400 to 800 mg once daily; maximum daily dose: 800 mg/<b>day</b>. Periodically assess maintenance treatment needs.</p>
<p style="text-indent:-2em;margin-left:6em;">Switching from immediate release to extended release: May convert patients from immediate-release to extended-release tablets at the equivalent total daily dose and administer once daily; individual dosage adjustments may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosing conversion:</i> To convert patients between immediate-release and extended-release tablets, administer the equivalent total daily dose. Administer immediate release 1 to 3 times daily and extended release once daily; individual dosage adjustments may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reinitiation of treatment:</i> Patients who have discontinued therapy for &gt;1 week should generally be retitrated using the initial dosing schedule; patients who have discontinued &lt;1 week can generally be reinitiated on their previous maintenance dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation</b>
<b> of psychosis therapy: </b>Children ≥10 years and Adolescents: The manufacturer and American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451'])">Ref</a></span>); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-16529334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-16529334'])">Ref</a></span>). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159748"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥10 years and Adolescents: Oral: No dosage adjustment necessary. <b>Note:</b> Removal by dialysis unlikely due to relatively high protein binding and large volume of distribution.</p></div>
<div class="block dohp drugH1Div" id="F51159749"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥10 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Oral: Initial: 25 mg once daily; increase dose by 25 to 50 mg/day to effective dose, based on individual clinical response and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Oral: Initial: 50 mg once daily; increase dose by 50 mg once daily to effective dose, based on individual clinical response and tolerability.</p></div>
<div class="block arsc drugH1Div" id="F54835645"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic activity of quetiapine at usual therapeutic doses is generally considered low relative to other second-generation antipsychotics (eg, clozapine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-10340682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-10340682'])">Ref</a></span>). However, dose-dependent increases in anticholinergic activity have been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16928430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16928430'])">Ref</a></span>). Anticholinergic effects may include <b>constipation</b>, <b>urinary retention </b>(case report in a patient receiving a high dose), <b>xerostomia</b>, and <b>blurred vision. </b>In older adults, some scales have classified quetiapine as having a high anticholinergic burden which may lead to new-onset<b> delirium, cognitive dysfunction</b>,<b> confusion, </b>and<b> falling. </b>However, there is no standardized tool for measuring anticholinergic burden in older adults and some scales have also rated quetiapine as low or moderate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31481872','lexi-content-ref-26813985','lexi-content-ref-29983780','lexi-content-ref-30484239','lexi-content-ref-25879993','lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31481872','lexi-content-ref-26813985','lexi-content-ref-29983780','lexi-content-ref-30484239','lexi-content-ref-25879993','lexi-content-ref-31342625'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; believed to be mediated primarily through active metabolite, norquetiapine antagonism at muscarinic receptors. Variability in conversion to norquetiapine may be a factor involved in inconsistency in reports associated with quetiapine’s anticholinergic adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31481872','lexi-content-ref-24062697','lexi-content-ref-Maan.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31481872','lexi-content-ref-24062697','lexi-content-ref-Maan.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Variable and dependent upon:</p>
<p style="text-indent:-2em;margin-left:8em;">• Total anticholinergic burden (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline cognitive function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Interindividual variability of the pharmacokinetic and pharmacodynamic parameters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cataracts</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is insufficient evidence that quetiapine is associated with an increased risk of <b>cataract</b> development in humans, despite warnings in the manufacturer's labeling. There are some case reports of cataracts occurring in patients receiving quetiapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15531330','lexi-content-ref-11384916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15531330','lexi-content-ref-11384916'])">Ref</a></span>); however, a large population-based, nested case control study did not find an association between atypical antipsychotics and risk of cataract development in patients with schizophrenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27061658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27061658'])">Ref</a></span>). The concern stems from animal research observing cataracts in beagles receiving quetiapine at 4 times the recommended human dose (this was not observed in other animal studies) and cataracts occurring in patients receiving certain phenothiazine neuroleptic medications, such as chlorpromazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12297603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12297603'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with dyslipidemia in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Dyslipidemia observed with quetiapine primarily manifests as hypertriglyceridemia (<b>increased serum triglycerides</b>), including cases of severe hypertriglyceridemia (&gt;600 mg/dL) and acute <b>pancreatitis </b>(some cases were fatal)<b>.</b> Hypercholesterolemia (<b>increased LDL cholesterol, increased serum cholesterol, decreased HDL cholesterol</b>) may also occur with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24987947','lexi-content-ref-30531242','lexi-content-ref-24719155','lexi-content-ref-24403385','lexi-content-ref-Morrato.2012','lexi-content-ref-17012695','lexi-content-ref-19724733','lexi-content-ref-26218604','lexi-content-ref-30700975','lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24987947','lexi-content-ref-30531242','lexi-content-ref-24719155','lexi-content-ref-24403385','lexi-content-ref-Morrato.2012','lexi-content-ref-17012695','lexi-content-ref-19724733','lexi-content-ref-26218604','lexi-content-ref-30700975','lexi-content-ref-25497507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747245','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747245','lexi-content-ref-26218604'])">Ref</a></span>). In cases of hypertriglyceridemia-induced acute pancreatitis due to quetiapine, almost all occurred within the first 8 months of an established dose and most frequently at 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30531242','lexi-content-ref-24719155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30531242','lexi-content-ref-24719155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of preexisting dyslipidemia or hypertriglyceridemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24719155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24719155'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population primarily due to cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Some authors consider quetiapine to have a high risk of hyperlipidemia, while others consider quetiapine’s risk to be intermediate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14981231','lexi-content-ref-15869022','lexi-content-ref-15025545','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14981231','lexi-content-ref-15869022','lexi-content-ref-15025545','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>). Overall, metabolic disturbances appear to be the greatest with clozapine and olanzapine and intermediate with quetiapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Quetiapine may cause extrapyramidal symptoms (EPS), also known as drug-induced movement disorders. Antipsychotics can cause 4 main EPS: Acute <b>dystonia, drug-induced parkinsonism,</b>
<b>akathisia</b>, and <b>tardive dyskinesia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16808551','lexi-content-ref-Gedam.2015','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16808551','lexi-content-ref-Gedam.2015','lexi-content-ref-20187598'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18794516','lexi-content-ref-29955499','lexi-content-ref-18615368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18794516','lexi-content-ref-29955499','lexi-content-ref-18615368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dsouza.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dsouza.2020'])">Ref</a></span>). Tardive dyskinesia: Time related (delayed); results from chronic exposure to dopamine 2 receptor antagonists leading to up-regulation of these receptors over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia</span>: Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (and even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism</span>: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia</span>: Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia</span>: Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist, and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with EPS)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dsouza.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dsouza.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dsouza.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dsouza.2020'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Quetiapine is considered to have a low propensity to cause EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16808551','lexi-content-ref-Dsouza.2020','lexi-content-ref-15163258','lexi-content-ref-18344731','lexi-content-ref-22057019','lexi-content-ref-28784372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16808551','lexi-content-ref-Dsouza.2020','lexi-content-ref-15163258','lexi-content-ref-18344731','lexi-content-ref-22057019','lexi-content-ref-28784372'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dsouza.2020','lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dsouza.2020','lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dsouza.2020','lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dsouza.2020','lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (Morgenstern 1993), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction <span style="text-decoration: underline">(</span>associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults &gt;75 years of age (may be risk factor due to age related muscle atrophy, cognitive impairment, or reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia</b>, <b>neutropenia</b>, and <b>thrombocytopenia</b> have rarely been reported with quetiapine monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arslan.2016','lexi-content-ref-11496032','lexi-content-ref-21058927','lexi-content-ref-15765830','lexi-content-ref-12635569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arslan.2016','lexi-content-ref-11496032','lexi-content-ref-21058927','lexi-content-ref-15765830','lexi-content-ref-12635569'])">Ref</a></span>). <b>Agranulocytosis</b>, including fatal agranulocytosis, has also been reported very rarely, including with monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28796018','lexi-content-ref-11722307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28796018','lexi-content-ref-11722307'])">Ref</a></span>). The majority of reports involving quetiapine-associated leukopenia or neutropenia involve patients receiving concomitant valproate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16930797','lexi-content-ref-25948288','lexi-content-ref-22561472','lexi-content-ref-19401471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16930797','lexi-content-ref-25948288','lexi-content-ref-22561472','lexi-content-ref-19401471'])">Ref</a></span>). In addition, there are case reports of <b>thrombotic thrombocytopenic purpura</b> (TTP) and <b>autoimmune hemolytic anemia</b> (AIHA) (pediatric patient) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30466224','lexi-content-ref-27340908','lexi-content-ref-15914516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30466224','lexi-content-ref-27340908','lexi-content-ref-15914516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; hypothesized as the same direct toxicity or immune-mediated destruction as clozapine, due to chemical structure similarities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arslan.2016','lexi-content-ref-12635569','lexi-content-ref-11722307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arslan.2016','lexi-content-ref-12635569','lexi-content-ref-11722307'])">Ref</a></span>). TTP and AIHA may occur due to a drug-induced immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30466224','lexi-content-ref-27340908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30466224','lexi-content-ref-27340908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>). For TTP, one case report described an onset within a few days after exposure with early thrombocytopenia, followed by delayed appearance (2 to 3 days) of microangiopathic hemolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15914516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15914516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia or low white blood cell count/absolute neutrophil count</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of valproate (which is also associated with causing blood dyscrasias and may increase quetiapine concentrations by 77% via a drug-drug interaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arslan.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arslan.2016'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with <b>hyperglycemia</b>, to varying degrees, which is a component of the metabolic syndrome observed with this pharmacologic class. Glycemic abnormalities range from mild insulin resistance or hyperglycemia to new-onset<b> diabetes mellitus</b> and <b>diabetic ketoacidosis,</b> including fatal cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23278567','lexi-content-ref-24403385','lexi-content-ref-28099349','lexi-content-ref-26218604','lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23278567','lexi-content-ref-24403385','lexi-content-ref-28099349','lexi-content-ref-26218604','lexi-content-ref-25497507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; new-onset diabetes has been observed within first 3 months to a median onset of 3.9 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20520598','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20520598','lexi-content-ref-18348593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• African American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &lt;35 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Exposure to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Type 2 diabetes mellitus: Extended exposure (mean: 17.2 months) in pediatric patients 10 to 18 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25844991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25844991'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Quetiapine is associated with a moderate risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypothyroidism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypothyroidism</b>, likely dose-related, has been observed rarely with quetiapine use, including cases requiring discontinuation or initiation of thyroid replacement therapy, and one case with spontaneous resolution without quetiapine discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10772436','lexi-content-ref-24956042','lexi-content-ref-19820433','lexi-content-ref-16633154','lexi-content-ref-20614417','lexi-content-ref-15645000','lexi-content-ref-32036034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10772436','lexi-content-ref-24956042','lexi-content-ref-19820433','lexi-content-ref-16633154','lexi-content-ref-20614417','lexi-content-ref-15645000','lexi-content-ref-32036034'])">Ref</a></span>). However, some studies have observed changes in total thyroxine (T4) levels only, without a significant increase in thyroid stimulating hormone (TSH) levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12364843','lexi-content-ref-15669892','lexi-content-ref-20614417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12364843','lexi-content-ref-15669892','lexi-content-ref-20614417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>The mechanism of action by which quetiapine causes hypothyroidism is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15645000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15645000'])">Ref</a></span>). It has been presumed to result from thyroid gland dysfunction (primary hypothyroidism); although, due to the presence of a low T4 without TSH changes, in many cases, a central [secondary] hypothyroidism rather than a primary hypothyroidism may also be a potential mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32036034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32036034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher quetiapine doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19820433','lexi-content-ref-20614417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19820433','lexi-content-ref-20614417'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">In general (regardless of quetiapine use):</p>
<p style="text-indent:-2em;margin-left:8em;">• Bipolar disorder (overt or subclinical hypothyroidism [more common]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808723'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (thyroid dysfunction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15669892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15669892'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium treatment (may induce or exacerbate preexisting hypothyroidism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21808723','lexi-content-ref-15645000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21808723','lexi-content-ref-15645000'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Of note, quetiapine is not approved for the treatment of dementia-related psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-25786075'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-Kales.2012','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-Kales.2012','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome </b>(NMS) in all ages, although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with quetiapine monotherapy, although most involve concomitant administration of another neuroleptic or other confounding conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-25580921','lexi-content-ref-18572981','lexi-content-ref-20520598','lexi-content-ref-26132604','lexi-content-ref-18628446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-25580921','lexi-content-ref-18572981','lexi-content-ref-20520598','lexi-content-ref-26132604','lexi-content-ref-18628446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689'])">Ref</a></span>). In a review of the few cases reported with quetiapine, the mean time of onset was 21 days (median: 9 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26132604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26132604'])">Ref</a></span>). However, there are many cases of NMS occurring months after stable antipsychotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pelonero.1998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pelonero.1998'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Disorganized speech or behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18572981','lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18572981','lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Intramuscular administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Quetiapine may cause <b>orthostatic hypotension</b> and accompanying <b>tachycardia </b>and<b> syncope </b>in adults, particularly with rapid titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-Nakamura.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-Nakamura.2016'])">Ref</a></span>). Orthostatic hypotension may result in subsequent <b>falling</b> and fracture, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25363460','lexi-content-ref-26813985','lexi-content-ref-25581312','lexi-content-ref-28146612','lexi-content-ref-28784372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25363460','lexi-content-ref-26813985','lexi-content-ref-25581312','lexi-content-ref-28146612','lexi-content-ref-28784372'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Orthostatic hypotension is attributed to alpha-1 adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; per the manufacturer's labeling, orthostatic hypotension is most common in the first few days of initiation or following a dosage increase; may also occur after only 1 dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21494344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21494344'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Known predisposing conditions (eg, hypovolemia/dehydration)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that also cause or exacerbate orthostatic hypotension (eg, tricyclic antidepressants, antihypertensive medications)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nakamura.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nakamura.2016'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Quetiapine has been associated with <b>prolonged QT interval on ECG</b>, including rare reports of <b>torsades de pointes </b>(TdP), predominately in the setting of overdose or in patients with multiple risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16808551','lexi-content-ref-11839370','lexi-content-ref-25168784','lexi-content-ref-12424166','lexi-content-ref-16096514','lexi-content-ref-16156840','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16808551','lexi-content-ref-11839370','lexi-content-ref-25168784','lexi-content-ref-12424166','lexi-content-ref-16096514','lexi-content-ref-16156840','lexi-content-ref-22114630'])">Ref</a></span>). Compared to other antipsychotics, quetiapine is generally associated with a low risk for QTc (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beach.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beach.2013'])">Ref</a></span>). In a study of healthy adult volunteers designed to evaluate the QTc prolongation potential of a single dose of quetiapine immediate release (100 mg), the mean change in QTc was 13.7 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26950553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26950553'])">Ref</a></span>). In another study in 27 healthy psychiatric patients reaching steady state on quetiapine 750 mg/day, the mean change in QTc was 5.7 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14709949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14709949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Likely dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25168784','lexi-content-ref-12176106','lexi-content-ref-27522397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25168784','lexi-content-ref-12176106','lexi-content-ref-27522397'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sedation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedated state</b> (<b>drowsiness</b>) is common with use; may cause nonadherence and impair physical and/or mental abilities resulting in subsequent <b>falling</b> and fracture, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25363460','lexi-content-ref-28141623','lexi-content-ref-26813985','lexi-content-ref-25581312','lexi-content-ref-31059621','lexi-content-ref-11768836','lexi-content-ref-28784372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25363460','lexi-content-ref-28141623','lexi-content-ref-26813985','lexi-content-ref-25581312','lexi-content-ref-31059621','lexi-content-ref-11768836','lexi-content-ref-28784372'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; sedation is believed to be due to H<sub>1</sub> antagonism leading to potential CNS depressant effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; per the manufacturer’s labeling, sedation is most common in the first few days of initiation or following a dosage increase.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics have been associated with sexual disorder in both males and females. Antipsychotic treatment has been associated with effects on all phases of sexual activity (libido, arousal, orgasm); however, many patients with schizophrenia experience more frequent sexual dysfunction, with or without antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16808551','lexi-content-ref-23737244','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16808551','lexi-content-ref-23737244','lexi-content-ref-20187598'])">Ref</a></span>). <b>Decreased libido</b>,<b> erectile dysfunction, </b>and <b>orgasm disturbance </b>have been reported with quetiapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12623765','lexi-content-ref-20048451','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12623765','lexi-content-ref-20048451','lexi-content-ref-21191308'])">Ref</a></span>)<b>. </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antipsychotic-induced sexual dysfunction has been attributed to many potential mechanisms, including dopamine receptor antagonism, dopamine D<sub>2</sub> receptor antagonism in the infundibular dopaminergic pathway causing hyperprolactinemia, histamine receptor antagonism, cholinergic receptor antagonism, and alpha-adrenergic receptor antagonism. Quetiapine is associated with a minimal risk of causing hyperprolactinemia in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12504073','lexi-content-ref-15954189','lexi-content-ref-23737244','lexi-content-ref-21267374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12504073','lexi-content-ref-15954189','lexi-content-ref-23737244','lexi-content-ref-21267374'])">Ref</a></span>); however, clinically significant prolactin levels have been observed in pediatric patients (ages 10 to 17 years).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperprolactinemia (although a correlation with sexual dysfunction has been observed, a relationship has not been confirmed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (the prevalence antipsychotic-induced sexual dysfunction in patients with schizophrenia is high [~50% to 60% compared with 31% of males in the general population]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22533871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22533871'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Quetiapine is usually associated with relatively lower rates of sexual dysfunction compared to other antipsychotics, such as risperidone and haloperidol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18338766','lexi-content-ref-15672600','lexi-content-ref-15954189','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18338766','lexi-content-ref-15672600','lexi-content-ref-15954189','lexi-content-ref-21191308'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body’s ability to regulate core body temperature, which may cause a potentially life-threatening heat stroke during predisposing conditions such as a heat wave or strenuous exercise. There are also several case reports of potentially life-threatening <b>hypothermia </b>associated with quetiapine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29197846','lexi-content-ref-18025545','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29197846','lexi-content-ref-18025545','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2A</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. In addition, antagonism of peripheral alpha-adrenergic receptors has also been suggested as a factor in the hypothermic effect, by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis, benzodiazepine use, alcohol intoxication, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Quetiapine is associated with significant <b>weight gain </b>(increase of ≥7% from baseline) in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-19861668','lexi-content-ref-25590213','lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-19861668','lexi-content-ref-25590213','lexi-content-ref-25497507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and plateaus over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-15998156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid weight gain in the initial period: Younger patients, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Quetiapine is considered to display moderate propensity for weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-28883731','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-28883731','lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F216241"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Actual frequency may be dependent upon dose and/or indication. Unless otherwise noted, frequency of adverse effects is reported for adult patients; spectrum and incidence of adverse effects similar in children (with significant exceptions noted).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased diastolic blood pressure (≥10 mm Hg; children and adolescents: 41% to 47%), increased systolic blood pressure (≥20 mm Hg; children and adolescents: 7% to 15%), orthostatic hypotension (children and adolescents: &lt;1%; adults: 2% to 7%; older adults: literature suggests the incidence may be as high as 18%) (Sajatovic 2008)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span>, tachycardia (≤11%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 2</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Source</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prescribing information</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prescribing information</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prescribing information</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prescribing information</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia and bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">404</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prescribing information</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Older adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">31</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sajatovic 2008</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">73</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">192</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">178</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia and bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">404</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (≤40 mg/dL: 9% to 20%)<span class="lexi-table-link-container"> (<a aria-label="Decreased HDL Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-decreased-hdl-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-hdl-cholesterol')">table 3</a>)</span><span class="table-link" style="display:none;">Decreased HDL Cholesterol</span>, increased serum cholesterol (7% to 18%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-cholesterol')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Serum Cholesterol</span>, increased serum triglycerides (8% to 28%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Triglycerides table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-triglycerides" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-triglycerides')">table 5</a>)</span><span class="table-link" style="display:none;">Increased Serum Triglycerides</span>, weight gain (dose related; 4% to 23%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain')">table 6</a>)</span><span class="table-link" style="display:none;">Weight Gain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased HDL Cholesterol" frame="border" id="lexi-content-decreased-hdl-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Decreased HDL Cholesterol</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">61</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">393</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">83</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">115</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">195</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Cholesterol" frame="border" id="lexi-content-increased-serum-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Increased Serum Cholesterol</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">83</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">66</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">56</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">463</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">250</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">85</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">106</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">128</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">134</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">92</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">718</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">232</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Triglycerides" frame="border" id="lexi-content-increased-serum-triglycerides" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Increased Serum Triglycerides</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">82</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">436</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">232</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">93</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">659</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">214</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain" frame="border" id="lexi-content-weight-gain" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Weight Gain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">111</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">44</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">92</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">68</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">193</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">554</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">295</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">110</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">209</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">138</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">391</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">907</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">299</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥7% of Body Weight</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia and bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">404</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased appetite (2% to 12%), xerostomia (children and adolescents: 4% to 10%; adults: 9% to 44%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 7</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">193</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">73</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 and 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia and bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">404</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (8% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (20%), dizziness (7% to 19%), drowsiness (18% to 57% including sedated state)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 8</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, extrapyramidal reaction (1% to 13%), fatigue (3% to 14%), headache (21%), withdrawal syndrome (12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">73</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">52%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia and bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">404</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (3%), palpitations (4%), syncope (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Syncope table link" class="lexi-table-link" data-table-id="lexi-content-syncope" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-syncope')">table 9</a>)</span><span class="table-link" style="display:none;">Syncope</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Syncope" frame="border" id="lexi-content-syncope" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Syncope</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">193</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,265</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">954</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (children and adolescents: 2% to 3%), hyperhidrosis (2%), pallor (children and adolescents: 1% to 2%), skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased free T4 (3%), decreased libido (2%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 10</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span>, decreased total T4 (≤3%), hyperglycemia (fasting glucose &lt;100 mg/dL to ≥126 mg/dL: 2%)<span class="lexi-table-link-container"> (<a aria-label="Hyperglycemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperglycemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperglycemia')">table 11</a>)</span><span class="table-link" style="display:none;">Hyperglycemia</span>, hyperprolactinemia (4%), increased LDL cholesterol (2% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Increased LDL Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-increased-ldl-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-ldl-cholesterol')">table 12</a>)</span><span class="table-link" style="display:none;">Increased LDL Cholesterol</span>, increased thirst (children and adolescents: 2%), increased thyroid stimulation hormone level (≤3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperglycemia" frame="border" id="lexi-content-hyperglycemia" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Hyperglycemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR and XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,907</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,346</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Normal to high (&lt;100 mg/dL to ≥126 mg/dL)</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased LDL Cholesterol" frame="border" id="lexi-content-increased-ldl-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Increased LDL Cholesterol</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">85</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">169</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">465</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">256</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">104</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">691</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">227</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 4%), anorexia (1% to 3%), constipation (2% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 13</a>)</span><span class="table-link" style="display:none;">Constipation</span>, decreased appetite (2%), diarrhea (children and adolescents: 5%), dyspepsia (5% to 7%), dysphagia (2%)<span class="lexi-table-link-container"> (<a aria-label="Dysphagia table link" class="lexi-table-link" data-table-id="lexi-content-dysphagia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dysphagia')">table 14</a>)</span><span class="table-link" style="display:none;">Dysphagia</span>, gastroenteritis (2%), nausea (5% to 10%), periodontal abscess (adolescents: 1% to 3%), toothache (2% to 3%), vomiting (5% to 8%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia and bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">404</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dysphagia" frame="border" id="lexi-content-dysphagia" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Dysphagia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Pollakiuria (2%), urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 15</a>)</span><span class="table-link" style="display:none;">Neutropenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neutrophil count &lt;1.5 x 10<sup>9</sup>/L</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neutrophil count &lt;1.5 x 10<sup>9</sup>/L</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3368</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1515</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neutrophil count &lt;1.0 x 10<sup>9</sup>/L</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (5%), increased serum aspartate aminotransferase (3%), increased serum transaminases (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (2% to 3%), aggressive behavior (children and adolescents: 1% to 3%), akathisia (≤5%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia table link" class="lexi-table-link" data-table-id="lexi-content-akathisia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia')">table 16</a>)</span><span class="table-link" style="display:none;">Akathisia</span>, anxiety (2% to 4%), ataxia (2%), confusion (2%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 17</a>)</span><span class="table-link" style="display:none;">Confusion</span>, decreased mental acuity (2%), disorientation (2%), disturbance in attention (2%), dysarthria (2% to 5%), dystonic reaction (≤6%)<span class="lexi-table-link-container"> (<a aria-label="Dystonic Reaction table link" class="lexi-table-link" data-table-id="lexi-content-dystonic-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dystonic-reaction')">table 18</a>)</span><span class="table-link" style="display:none;">Dystonic Reaction</span>, hypersomnia (2% to 3%), hypoesthesia (2%), irritability (3% to 5%), lethargy (2% to 5%), migraine (2%), pain (7%), paresthesia (2% to 3%), parkinsonism (≤6%)<span class="lexi-table-link-container"> (<a aria-label="Parkinsonism table link" class="lexi-table-link" data-table-id="lexi-content-parkinsonism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-parkinsonism')">table 19</a>)</span><span class="table-link" style="display:none;">Parkinsonism</span>, restless leg syndrome (2%), restlessness (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia" frame="border" id="lexi-content-akathisia" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Akathisia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">193</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">73</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">750 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dystonic Reaction" frame="border" id="lexi-content-dystonic-reaction" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Dystonic Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">73</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">750 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Parkinsonism" frame="border" id="lexi-content-parkinsonism" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Parkinsonism</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">73</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">800 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">74</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">53</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1% to 4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">750 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">48</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 4%), asthenia (1% to 5%), back pain (1% to 3%), dyskinesia (3% to 4%), limb pain (2%), muscle rigidity (3%), muscle spasm (2% to 3%), myalgia (2%), neck pain (2%), stiffness (children and adolescents: 3%), tremor (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (2%), blurred vision (2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Blurred Vision table link" class="lexi-table-link" data-table-id="lexi-content-blurred-vision" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-blurred-vision')">table 20</a>)</span><span class="table-link" style="display:none;">Blurred Vision</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Blurred Vision" frame="border" id="lexi-content-blurred-vision" rules="all">
<caption style="text-align:center;">
<b>Quetiapine: Adverse Reaction: Blurred Vision</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Quetiapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children &amp; adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar disorder, depressive episode</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">698</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">347</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">400 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">XR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">300 to 800 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">951</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">319</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1% to 3%), dyspnea (1% to 3%), epistaxis (adolescents: 3%), nasal congestion (3% to 6%), paranasal sinus congestion (2% to 3%), pharyngitis (4%), rhinitis (3%), sinus headache (2%), sinusitis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Endocrine &amp; metabolic: Decreased T3 blood level</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertensive crisis (one case in a child with a history of hypertension)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Falling, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (Chou 2017), atrial flutter (Chou 2017), cardiomyopathy (Coffey 2011), colonic ischemia, hypersensitivity angiitis (Ram 2019), myocarditis (Bhogal 2018), prolonged QT interval on ECG (Kim 2016), torsades de pointes (Vieweg 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Lasić 2013), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (new onset ) (Nanasawa 2017; Nielson 2010), diabetic ketoacidosis (Ely 2013), hyponatremia (Aruachan 2020), hypothyroidism (Feret 2000), SIADH (Koufakis 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal obstruction, pancreatitis (Alastal 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (Nagaraj 2009), nocturia, orgasm disturbance (Nagaraj 2009), urinary retention (high-dose therapy) (Sokolski 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Glocker 2017), autoimmune hemolytic anemia (Huynh 2005), eosinophilia (Chen 2015), leukopenia (Fan 2015), thrombocytopenia (Arslan 2016), thrombotic thrombocytopenic purpura (Husnain 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Hajj 2004), hepatic necrosis, hepatitis (Das 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Torroba Sanz 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Choreoathetosis (Netherlands Pharmacovigilance Centre Lareb 2006), cognitive dysfunction (El-Saifi 2016), delirium (Almeida 2019), diabetes mellitus with hyperosmolar coma, hypothermia (Zonnenberg 2017), neuroleptic malignant syndrome (Schattner 2016), hypothermia (Zonnenberg 2017), retrograde amnesia, sleep apnea, suicidal ideation (Katila 2013), tardive dyskinesia (Hou 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hypokinesia (Netherlands Pharmacovigilance Centre Lareb 2006), rhabdomyolysis (Li 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (Fraunfelder 2004), intraoperative floppy iris syndrome (Chatziralli 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Obstructive sleep apnea syndrome (Health Canada 2016; Shirani 2011)</p></div>
<div class="block coi drugH1Div" id="F216253"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to quetiapine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F216238"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cancer (eg, breast cancer): The clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic disease or impairment; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention (eg, benign prostatic hyperplasia): Use with caution in patients with urinary retention as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878617"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder and schizophrenia is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions.</p>
<p style="text-indent:0em;margin-top:2em;">Unlike adults, hypertension (as defined: systolic blood pressure increased by ≥20 mm Hg, diastolic blood pressure increased by ≥10 mm Hg) has been reported in children and adolescent patients occurring at any time during clinical trials; hypertensive crisis was also reported in children with history of hypertension.</p></div>
<div class="block foc drugH1Div" id="F216247"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SEROquel: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SEROquel XR: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F216234"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F216255"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (QUEtiapine Fumarate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $8.87 - $15.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $1.25 - $15.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.50 - $17.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.75 - $22.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $2.29 - $27.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (SEROquel XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $9.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $17.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $19.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $25.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $30.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (QUEtiapine Fumarate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.35 - $4.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.56 - $6.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.56 - $6.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $1.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $1.14 - $12.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $16.95 - $17.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $1.68 - $19.93</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (SEROquel Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $4.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $7.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $8.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $15.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $19.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $23.26</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868089"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SEROquel: 25 mg, 100 mg, 200 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SEROquel XR: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 150 mg, 200 mg, 300 mg, 400 mg</p></div>
<div class="block adm drugH1Div" id="F5094101"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Administer without food or with a light meal (≤300 calories), preferably in the evening. Swallow tablet whole; do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasogastric/enteral tube (off-label route): Hold tube feeds for 30 minutes before administration; flush with 25 mL of sterile water. Crush dose using immediate-release formulation, mix in 10 mL water and administer via NG/enteral tube; follow with a 50 mL flush of sterile water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19915454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19915454'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613762"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablet: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablet: Administer without food or with a light meal (≤300 calories), preferably in the evening. Swallow tablet whole; do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasogastric/enteral tube: Immediate-release tablet: Based on experience in adult patients: Hold tube feeds for 30 minutes before administration; flush with 25 mL of sterile water. Crush dose, mix in 10 mL water, and administer via NG/enteral tube; follow with a 50 mL flush of sterile water. Restart tube feedings after drug administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19915454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19915454'])">Ref</a></span>).</p></div>
<div class="block meg drugH1Div" id="F7874967"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Seroquel: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F020639s072lbl.pdf%23page%3D49&amp;token=R6lhCPM3n9rOOMnue7%2B9YcQTVJWc6v6CNAuhiTPQXTYUuQF9xQLUtk%2B3Ci6WbaTs76T3ByQWYeb7yoZRjpCMdayo5O03%2Bx4Mj3%2F4Plyis0BDcOf9SSfgyMzJo%2FGQWJ6v&amp;TOPIC_ID=9570" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020639s072lbl.pdf#page=49</a></p>
<p style="text-indent:-2em;margin-left:4em;">Seroquel XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022047s046lbl.pdf%23page%3D53&amp;token=F9nvU3Xs5AXX%2B0Y%2F4f7JDXXWKmLOYlGwv4U7KeOo4GTdi48vuSzINPimIEES1%2BPYt2n1BsKadW7v6rePSwTfYCpac9IfCVJsxbYl6eNEJMP6eVuOQVzlSDOrRKWfvzpt&amp;TOPIC_ID=9570" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022047s046lbl.pdf#page=53</a></p></div>
<div class="block use drugH1Div" id="F216250"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b> Acute treatment of mania (both immediate release and extended release), episodes with mixed features (extended release only), and hypomanic episodes (off label) associated with bipolar I disorder, both as monotherapy and as an adjunct to antimanic therapy; maintenance treatment of bipolar I disorder, as monotherapy (off label) or as an adjunct to antimanic therapy; acute treatment of bipolar major depression, as monotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (extended release only):</b> Adjunctive therapy in patients with an inadequate response to antidepressants for the treatment of major depressive disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b> Treatment of schizophrenia.</p></div>
<div class="block off-label drugH1Div" id="F25471616"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation/aggression and psychosis associated with dementia, severe or refractory (alternative agent); Agitation and/or delirium, ICU (alternative agent); Delusional infestation (delusional parasitosis); Generalized anxiety disorder (alternative agent); Major depressive disorder (unipolar), monotherapy (alternative agent); Obsessive-compulsive disorder, treatment-resistant (augmentation); Posttraumatic stress disorder, adjunct to antidepressants or monotherapy (alternative agent); Psychosis in Parkinson disease</p></div>
<div class="block mst drugH1Div" id="F216306"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">QUEtiapine may be confused with OLANZapine</p>
<p style="text-indent:-2em;margin-left:4em;">Seroquel may be confused with Desyrel, Seroquel XR, Serzone, SINEquan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F216291"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F216242"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Armodafinil: May decrease the serum concentration of QUEtiapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: QUEtiapine may increase serum concentrations of the active metabolite(s) of CarBAMazepine. CarBAMazepine may decrease the serum concentration of QUEtiapine.  Management: Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing carbamazepine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of ClomiPRAMINE. QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of ClomiPRAMINE. This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of QUEtiapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of QUEtiapine. Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of QUEtiapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of QUEtiapine. Management: In quetiapine treated patients, reduce quetiapine to one-sixth of original dose after starting a strong CYP3A4 inhibitor. In those on strong CYP3A4 inhibitors, start quetiapine at lowest dose and up-titrate as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of QUEtiapine. Dabrafenib may decrease the serum concentration of QUEtiapine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Also monitor for reduced quetiapine efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of DroPERidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QUEtiapine. Encorafenib may decrease the serum concentration of QUEtiapine. Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Additionally, monitor for QTc interval prolongation and ventricular arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fexinidazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Flupentixol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of Imipramine. This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of QUEtiapine. Kratom may increase the serum concentration of QUEtiapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Propofol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of QUEtiapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of QUEtiapine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QUEtiapine. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine. Management: Monitor for increased quetiapine toxicities including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of QUEtiapine. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of QUEtiapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): QUEtiapine may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QUEtiapine.  Management: Reduce the quetiapine dose to one-sixth of the regular dose when initiating these strong CYP3A4 inhibitors. In patients already receiving these strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and titrate cautiously as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of QUEtiapine. Management: Quetiapine dose increases to as much as 5 times the regular dose may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing St John's wort. Monitor closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: QUEtiapine may enhance the CNS depressant effect of Trimeprazine. Trimeprazine may increase the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: QUEtiapine may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F216266"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">In healthy volunteers, administration of quetiapine (immediate release) with food resulted in an increase in the peak serum concentration and AUC by 25% and 15%, respectively, compared to the fasting state. Administration of the extended-release formulation with a high-fat meal (~800-1000 calories) resulted in an increase in peak serum concentration by 44% to 52% and AUC by 20% to 22% for the 50 mg and 300 mg tablets; administration with a light meal (≤300 calories) had no significant effect on the C<sub>max</sub> or AUC. Management: Administer without food or with a light meal (≤300 calories).</p></div>
<div class="block rep_considerations drugH1Div" id="F53604546"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Quetiapine may cause hyperprolactinemia, which may decrease reproductive function in both males and females.</p>
<p style="text-indent:0em;margin-top:2em;">If treatment with atypical antipsychotic is needed in a woman planning a pregnancy, use of quetiapine may be considered (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F6831003"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Quetiapine crosses the placenta and can be detected in cord blood (Newport 2007). Congenital malformations have not been observed in humans (based on available data). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment algorithms have been developed by the American College of Obstetricians and Gynecologists (ACOG) and the American Psychiatric Association (APA) for the management of depression in women prior to conception and during pregnancy (Yonkers 2009). The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy are limited; as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is initiated during pregnancy, use of quetiapine may be considered (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to quetiapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>
<div class="block brc drugH1Div" id="F9850204"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Quetiapine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of quetiapine is 0.43% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 200 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of quetiapine was calculated using a milk concentration of 62 mcg/L, providing an estimated daily infant dose via breast milk of 9.3 mcg/kg/day. This milk concentration was obtained following maternal administration of quetiapine 200 mg daily throughout pregnancy and after delivery; sampling occurred 3 weeks postpartum. The RID was calculated using the actual maternal weight. The maximum concentration of quetiapine in breast milk occurred 1 hour after the maternal dose (Lee 2004). In one case report, quetiapine was measured in the serum of a breastfed infant; the concentration was 6% of the maternal level obtained at the same time (Rampono 2007). Adverse events have not been reported in breastfeeding infants (Larsen 2015; Pacchiarotti 2016; Uguz 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. In general, infants exposed to second-generation antipsychotics via breast milk should be monitored weekly for the first month of exposure for symptoms such as appetite changes, insomnia, irritability, or lethargy (Uguz 2016). When an antipsychotic medication is needed in a breastfeeding woman, quetiapine may be used (Larsen 2015; Pacchiarotti 2016; Uguz 2016).</p></div>
<div class="block dic drugH1Div" id="F216256"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer extended-release tablet without food or with a light meal (≤300 calories).</p></div>
<div class="block mop drugH1Div" id="F216245"><span class="drugH1">Monitoring Parameters</span>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Frequency of Antipsychotic Monitoring<sup>a,b</sup></b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Monitoring parameter</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Frequency of monitoring</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Comments</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>For all monitoring parameters, it is appropriate for check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> ADA 2004; APA [Keepers 2020]; De Hert 2011; Gugger 2011; manufacturer's labeling.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Risk factors for tardive dyskinesia include age &gt;55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or CNS injury; past or current EPS.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>e</sup> Gunther 2023; expert opinion.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adherence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Blood chemistries (electrolytes, renal function, liver function, TSH)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center">
<p style="text-indent:0em;">For patients with liver cirrhosis, liver biochemistries should be obtained at baseline, then at 6 weeks and every 3 months during the first year of therapy, then annually thereafter or when clinically indicated.<sup>e</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">CBC</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">As clinically indicated</p></td>
<td align="center">
<p style="text-indent:0em;">Check frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extrapyramidal symptoms</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>c</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fall risk</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fasting plasma glucose/HbA<sub>1c</sub></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">12 weeks after initiation and dose change; annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check more frequently than annually if abnormal. Follow diabetes guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Lipid panel</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">12 weeks after initiation and dose change; annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check more frequently than annually if abnormal. Follow lipid guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mental status and alertness</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Metabolic syndrome history</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Prolactin</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hyperprolactinemia symptoms: Changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tardive dyskinesia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>d</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Vital signs (BP, orthostatics, temperature, pulse, signs of infection)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change.</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Weight/Height/BMI</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">8 and 12 weeks after initiation and dose change; quarterly</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome.</p>
<p style="text-indent:0em;text-align:left;">Consider changing antipsychotic if BMI increases by ≥1 unit.</p>
<p style="text-indent:0em;text-align:left;">Some experts recommend checking weight and height at every visit.</p></td></tr></tbody></table></div>
<div class="block rer drugH1Div" id="F55476430"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Draw trough just before next dose (Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic reference range: 100 to 500 ng/mL (SI: 261 to 1305 nmol/L) (Hiemke 2018). <b>Note:</b> Dosing should be based on therapeutic response as opposed to serum concentrations; however, therapeutic drug monitoring can be used to confirm adherence (APA [Keepers 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Laboratory alert level: 1,000 ng/mL (SI: 2,610 nmol/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F216237"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Quetiapine is a dibenzothiazepine atypical antipsychotic. It has been proposed that this drug's antipsychotic activity is mediated through a combination of dopamine type 2 (D<sub>2</sub>) and serotonin type 2 (5-HT<sub>2</sub>) antagonism. It is an antagonist at multiple neurotransmitter receptors in the brain: Serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub>, dopamine D<sub>1</sub> and D<sub>2</sub>, histamine H<sub>1</sub>, and adrenergic alpha<sub>1</sub>- and alpha<sub>2</sub>-receptors;  but appears to have no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors. Norquetiapine, an active metabolite, differs from its parent molecule by exhibiting high affinity for muscarinic M1 receptors.</p>
<p style="text-indent:0em;margin-top:2em;text-align:justify;">Antagonism at receptors other than dopamine and 5-HT<sub>2</sub> with similar receptor affinities may explain some of the other effects of quetiapine. The drug's antagonism of histamine H<sub>1</sub>-receptors may explain the somnolence observed. The drug's antagonism of adrenergic alpha<sub>1</sub>-receptors may explain the orthostatic hypotension observed. </p></div>
<div class="block phk drugH1Div" id="F216252"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, depressive episode: Initial effects may be observed within 1 week of treatment with continued improvements through 6 weeks (Cruz 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Generalized anxiety disorder: Extended release: Initial effects may be observed within 4 to 7 days with continued improvements over 8 weeks (Bandelow 2010; Khan 2011; Merideth 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Major depressive disorder, unipolar: Initial effects may be observed within 1 week with continued improvements over 6 to 12 weeks (Wen 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapidly absorbed following oral administration; high-fat meals (800 to 1,000 calories) increased quetiapine XR C<sub>max</sub> 44% to 52% and AUC 20% to 22% following administration of 50 and 300 mg tablets, respectively; light meals (300 calories) had no effect; parent compound AUC and C<sub>max</sub> were 41% and 39% lower, respectively, in pediatric patients (10 to 17 years) compared to adults when adjusted for weight, but pharmacokinetics of active metabolite were similar to adult values after adjusting for weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 10 ± 4 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: 83%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic; via CYP3A4; forms the metabolite N-desalkyl quetiapine (active) and two inactive metabolites [sulfoxide metabolite (major metabolite) and parent acid metabolite]</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 100% (relative to oral solution)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 12 to 17 years: Quetiapine: 5.3 hours (McConville 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Mean: Terminal: Quetiapine: ~6 hours; Extended release: ~7 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolite: N-desalkyl quetiapine: 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 12 to 17 years: Immediate release: 0.5 to 3 hours (McConville 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Immediate release: 1.5 hours; Extended release: 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (73% as metabolites, &lt;1% of total dose as unchanged drug); feces (20%)</p></div>
<div class="block phksp drugH1Div" id="F51220173"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: CrCl 10 to 30 mL/minute had 25% lower clearance; plasma concentrations were within the range of concentrations seen in normal subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: 30% lower clearance; AUC and C<sub>max</sub> is 3-fold higher.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Clearance reduced 40%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F216257"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adazio | Asero xr | Quetta | Quetta xr | Qupinex | Rezal xr | Seroquel xr | Soleil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Afidat | Biatrix | Dendritex | Inquetia | Kenantis | Quetiaros | Rostrum | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hedonin xr | Quesery | Quetialan | Quetiapin | Quetiapin +pharma | Quetiapin 1A pharma | Quetiapin accord | Quetiapin bluefish | Quetiapin Easypharm | Quetiapin g l | Quetiapin G.L. | Quetiapin Genericon | Quetiapin krka | Quetiapin neuraxpharm | Quetiapin ratiopharm | Quetiapin sandoz | Quetiapin stada | Seroquel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aliquen | Alkem quetiapine | Apo quetiapine | Apotex quetiapine | Apx quetiapine | Auro quetiapine | Chemmart quetiapine | Delucon | Dp quetiapine | Kaptan | Ketizenol | Noumed quetiapine | Pharmacor quetiapine | Pharmacy choice quetiapine | Qualez | Quepine xr | Quetapen | Quetia | Quetiaccord | Quetiapine actavis | Quetiapine an | Quetiapine apotex | Quetiapine as xr | Quetiapine ascent | Quetiapine ch | Quetiapine drla | Quetiapine ga | Quetiapine gh | Quetiapine Pfizer | Quetiapine ranbaxy | Quetiapine rbx | Quetiapine sandoz | Quetiapine sg | Quetiapine spr | Quetiapine synthon | Quetiapine tih | Quetiapine watson | Quetin | Quipine | Sequase | Sequase xr | Serapine xr | Seronia | Seroquel | Seroquel xr | Serotiapine xr | Stada quetiapine | Syquet | Syquet xr | Terry white chemists quetiapine | Terry white quetiapine | Tevatiapine xr | Tiava xr</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Qpine | Queta | Queta xr | Quiet | Quiet 200 xr | Qutap | Qutipin | Qutipin sr | Renapine | Seroquet | Tiapine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mylaquel | Quetiapin actavis | Quetiapin sandoz | Quetiapine Accord Healthcare | Quetiapine apotex | Quetiapine eg | Quetiapine krka | Quetiapine mylan | Quetiapine retard EG | Quetiapine teva | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Brevenox | Centroqueen | Hedonin | Kvelux | Kventiax | Queticon | Seroquel xr | Serotiapine | Setinin | Tevaquel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aebol | Atip | Atip xr | Fum quetiapina | Fumarato de quetiapina | Hemifumarato de quetiapina | Kitapen | Neotiapim | Queopine | Quepsia lp | Querok | Queropax | Quet | Quet xr | Quetiapin | Quetiapina | Quetibux | Quetiel | Quetipin | Quetipin lp | Quetros | Seroquel | Tracox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Quetiapin actavis | Quetiapin helvepharm | Quetiapin Mepha | Quetiapin sandoz | Quetiapin spirig | Quetiapin spirig hc | Quetiapin xr sandoz | Quetiapin xr spirig hc | Quetiapin xr zentiva | Quetiapin zentiva | Sequase | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Asicot | Eufrenim | Norsic | Nortium | Nortium xr | Quetiazic | Quetidin | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Qi wei | Seroquel | Shu si | Tai lun zuo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Exquia | Inaven | Ketian | Norsic | Quepina | Quetiamet | Quetiapina | Quetiapina Colmed | Quetiazic | Quetirel | Quetisfren | Quitide | Qutipin | Seroquel | Tiamax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo-quetiapin | Derin | Derin prolong | Equeta | Hedonin | Ketilept | Kventiax | Kventiax prolong | Nantarid | Questax | Quetapo | Quetiapin | Quetiapin actavis | Quetiapin bluefish | Quetiapin GSK | Quetiapin mylan | Quetiapin neuraxpharm | Quetiapin pmcs | Quetiapin ratiopharm | Quetiapin reg europe | Quetiapin sandoz | Quetiapin Teva | Quetiapin xantis | Quetiapine Orion | Quetiapine Polpharma | Quetrop | Resirentin | Seroquel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Quentiax | Quetiapin | Quetiapin 1A pharma | Quetiapin abz | Quetiapin accord | Quetiapin Acis | Quetiapin actavis | Quetiapin aluid | Quetiapin aristo | Quetiapin Aurobindo | Quetiapin betapharm | Quetiapin biomo | Quetiapin bluefish | Quetiapin CT | Quetiapin devatis | Quetiapin fair med | Quetiapin Farmapro | Quetiapin hennig | Quetiapin Heumann | Quetiapin hexal | Quetiapin hormosan | Quetiapin mylan | Quetiapin neuraxpharm | Quetiapin Pfizer | Quetiapin puren | Quetiapin Q | Quetiapin ratiopharm | Quetiapin stada | Quetiapin tad | Quetiapin zentiva | Quetiapine puren | Seroquel</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Seroquel</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adaptus | Asicot | Cidalan | Edagan | Edagan xr | Equiatin | Nervodep | Norsic | Placidin | Psiquet | Quetaxil | Quetiap | Quetiapina ethical | Quetiapina mamey | Quetiazic xr | Quetidin | Quetil | Serenil | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Catepsin | Ketipina xr | Norsic | Quetiazic | Quetiazic xr | Quetidin | Quetirel | Qutipin | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hedonin | Ketipinor | Kventiax | Kventiax sr | Quetiapine Polpharma | Quetiapine teva | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Psyquel | Quadel | Quetiasu | Quetiazic | Quitapex | Seroquel | Spiraquet</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ilufren | Psicotric | Qudix | Quentiax | Quetiamylan | Quetiapina accord | Quetiapina actavis | Quetiapina alter | Quetiapina amneal | Quetiapina apotex | Quetiapina aurobindo | Quetiapina aurovitas | Quetiapina cinfa | Quetiapina combix | Quetiapina Davur | Quetiapina juste | Quetiapina kern pharma | Quetiapina krka | Quetiapina mylan | Quetiapina Normon | Quetiapina orion | Quetiapina pensa | Quetiapina pharma combix | Quetiapina qualigen | Quetiapina ratiopharm | Quetiapina Sandoz | Quetiapina sandoz farmaceutica | Quetiapina stada | Quetiapina Tarbis | Quetiapina TecniGen | Quetiapina teva | Quetiapina vegal | Quetiapina winthrop | Rocoz | Seroquel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Biquetan | Ketipinor | Quetiapin | Quetiapin accord | Quetiapin actavis | Quetiapin Arrow | Quetiapin hexal | Quetiapin ratiopharm | Quetiapin sandoz | Quetiapine teva | Seroquel</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Quetiapine accord lp | Quetiapine arrow | Quetiapine cristers | Quetiapine evolugen lp | Quetiapine krka | Quetiapine krka lp | Quetiapine mylan | Quetiapine teva LP | Quetiapine zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alaquet XL | Atrolak | Biquelle XL | Brancico xl | Ebesque XL | Mintreleq XL | Psyquet xl | Quetiapine | Quettor | Seotiapim | Seroquel | Sondate xl | Tenprolide | Zaluron XL</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anaquetan xr | Etiapin | Ketipine | Matepil | Megazon | Quapianol | Quental | Quepin | Quetiapine tad | Quetiapine/actavis | Quetiapine/ariti | Quetiapine/Generics | Quetiapine/teva | Quetiapine/teva xr | Secuelia xr | Seropin | Seroquel xr | Serotiapin | Serotiapin xr | Tiaquel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alvoquel | Apo quetiapine | Kesaquil | Pms quetiapine | Quantia | Quesero | Quetiapine | Quetiapine teva | Seroquel | Setinin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kventiax | Kvetiapin Genera | Kvetiapin PharmaS | Loquen | Loquen XR | Q pin | Quelapin | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Equepin | Ketilept | Kventiax sr | Lantiapin | Nantarid | Quetiapin bluefish | Quetiapin mylan | Quetiapin Pliva | Quetiapin sandoz | Quetiapine Orion | Quetiapine teva | Quetiapine Vipharm | Resirentin | Seroquel | Setinin | Stadaquel</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Quetvell | Seroquel | Soroquin xr</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Geroquel | Notiabolfen XL | Quentiax sr | Quetex | Quetiapine | Seropia | Seroquel | Setinin | Tevaquel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Seroquel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adequet | Aquiti | Pincalm | Placidin | Psynil | Q pin | Q win | Q-Mind | Qta | Qte | Quatisure | Quel | Quetalent | Quetia | Quetic | Quetigress | Quital | Quitibrus | Qupex | Qupin | Quser | Quser xl | Qutace | Qutan | Quteklas | Quticad | Quticool | Qutipin | Qutiwel sr | Seropax | Seroquin | Sizoquit | Socalm</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Serequapine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Quentiax | Quetiapina | Quetiapina accord | Quetiapina actavis | Quetiapina doc | Quetiapina eg | Quetiapina mylan | Quetiapina orion | Quetiapina pensa | Quetiapina Sandoz | Quetiapina teva | Quetiapina zentiva | Seroquel</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Quel XR | Quitide | Quzal | Rezal xr | Seropin | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bipresso | Quetiapine | Quetiapine fumarate ffp | Quetiapine Pfizer | Seroquel</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Megazon | Quti | Qutipin | Seroquel | Seroquel xr | Torquite sr</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bearquel | Cacepin | Cacepin sr | Daewoongbio quetiapine | Easytapine | Hanwha quetiapine | I quapine | Ketapin | Mirae quetiapine | Myungmoon quetiapine | Pms quetiapine | Q rokel | Q rokel xr | Quaichi | Quapine | Quatine | Quepine | Quetapin | Quetapin xr | Quetiapine | Quetin | Quetina | Quety | Quety sr | Qurokel | Qutiapine | Qutima | Qutipin | Samsung quetiapine | Seroapine | Seroq | Seroquel | Seroquel ir | Seroquel xr | Serotipin | Sinsin quetiapine | Smoodipin | Td pine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Adazio | Quetta xr | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pms quetiapine | Rezal xr | Rocoz | Seropine | Seroquel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hedonin | Ketipinor | Kventiax | Loquen | Nantarid | Quetiapine | Quetiapine accord | Quetiapine actavis | Quetiapine Polpharma | Quetiapine teva | Quetirel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Quetiapin ratiopharm | Quetiapin sandoz | Quetiapine apotex | Quetiapine eg | Quetiapine retard EG | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hedonin | Kventiax | Loquen | Nantarid | Quetiapin | Quetiapine actavis | Quetiapine Polpharma | Quetiapine teva | Quetirel | Seroquel xr | Sofrel</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Axonyl | Esperal | Quetiaphi LP | Seroquel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alrex | Apego | Aretaeus | Armopan | Bartilixima | Dextion | Dextion xr | Euaral | Fishre | Gaelorax | Galambral | Kronalt | Nipekel | Q-Mind | Quermez | Quetiapina | Rayar | Rirabago | Seroquel | Seroquel xr | Tim asf | Zoqualo</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo quetiapine | Ketipinor | Quetiapine | Quetiapine Winthrop | Qutero | Seroquel | Seroquel xr | Tisderan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Quetiapine sandoz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Quetiapine | Quetiapine aurobindo retard | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Quetiapin actavis | Quetiapin Amneal | Quetiapin aristo | Quetiapin Copyfarm | Quetiapin hexal | Quetiapin ratiopharm | Quetiapin sandoz | Quetiapine accord | Quetiapine teva | Seroquel</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Quetapel | Quetiapine dr reddy | Seroquel</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Edagan | Edagan xr | Neurotol | Norsic | Q pin | Quetiazic xr | Serenase | Seroquel xr | Squro</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ketilept | Q win | Qtipine | Quantia | Quekline | Quetadin | Quetiapro | Seroquel | Serotia | Sykoquit | Victus</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Angepine | Angepine xr | Cequel | Equp | Equp d | Etal | Evokalm | Genpine xr | Karidef | Linque | Neoquel | Neoquel xr | Nubaquel | Pequit | Pequit xr | Pinetop | Pinetop xr | Q med | Q par | Q t pine | Q t pine xr | Q well | Q win | Qtipan | Qtp | Qualey | Quesanic | Quetogen | Quit xr | Quitalax | Quitapin | Quitin | Qupin | Qupixan | Qusel | Qutapin | Qutec | Qutia | Qutin | Qutipip | Quto | Qutyl | Quwa | Quziq | Sadoquil | Sadoquil xr | Schizomark | Schizomark xr | Schizonil | Seroquel | Sycosin | Tiapin | Togal | Winpine | Xaspine | Ziapine | Ziapine xr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apotiapina | Atrolak | Bonogren | Bonogren sr | Etiagen | Etiagen XR | Gentiapin | Kefrenex | Ketiap | Ketilept retard | Ketipinor | Ketrel | Kvelux SR | Kventiax sr | Kwetaplex | Kwetax | Kwetinor | Loquen | Nantarid | Pinexet | Pinexet SR | Poetra | Quentapil | Quetiapine accord | Quetiser | Seroquel | Stadaquel | Symquel | Vorta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Quetiapine | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alzen | Kventiax | Quetamed | Quetiapin qualigen | Quetiapina | Quetiapina accord | Quetiapina alter | Quetiapina anfarm | Quetiapina Aristo | Quetiapina bluepharma | Quetiapina Bruliva | Quetiapina cinfa | Quetiapina Daquimed | Quetiapina fair med | Quetiapina Farmoz | Quetiapina generis | Quetiapina kventiax | Quetiapina Labesfal | Quetiapina mepha | Quetiapina mylan | Quetiapina Rocoz | Quetiapina TAD | Quetiapina tolife | Quetiapina vianex | Quetiapina wynn | Quetiapina zentiva | Seroquel</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Catepsin | Cautival | Cautival xr | Edagan | Edagan xr | Quetiapin | Quetiapina pasteur | Quetiazic | Quetiazic xr | Quetidin | Seroquel</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ketya | Seroquel | Seroquel XR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Hedonin | Ketilept | Kventiax | Kventiax ep | Netiapin | Q mind | Quersus | Quetiapina accord | Quetiapina zentiva | Quetiapine teva | Quetrop | Uniquet</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cumental | Gedonin | Ketilept | Kventiax | Kventiax sr | Lacvel | Laquel | Nantarid | Quepinex | Quetiap | Quetiapine | Quetiapine alium | Quetiapine canon prolong | Quetiapine stada | Quetiapine vial | Quetitex | Qutipin | Seroquel | Servitel | Victoel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adazio | Apo-quetiapin | Atapina | Pms quetiapine | Qatpen | Qatpen xr | Quenta xr | Quetal xr | Quetta | Quetta xr | Quzal | Sequit | Serogen | Seroquel | Sicopin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Biquetan | Ketipinor | Kvetiapin Ebb | Quetiapin 1A Farma | Quetiapin actavis | Quetiapin Amneal | Quetiapin Arrow | Quetiapin Ebb | Quetiapin fair med | Quetiapin krka | Quetiapin medical valley | Quetiapin Orion | Quetiapin sandoz | Quetiapin stada | Quetiapine accord | Quetiapine teva | Seroquel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo quetiapine | Ketipinor | Quetiapine | Seroquel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kvelux | Kvelux SR | Kventiax | Kventiax sr | Loquen | Loquen sr | Quepigal | Quetiapin accord | Seroquel | Setinin | Treksta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Derin | Derin prolong | Equeta | Hedonin | Hedonin xr | Ketilept | Kventiax | Nantarid | Qubel | Questax | Quetiapin mylan | Quetiapin pmcs | Quetiapin ratiopharm | Quetiapin sandoz | Quetiapin Saneca | Quetiapin Teva | Quetiapin zentiva sr | Quetiapine accord | Quetiapine Bluefish | Quetiapine Orion | Quetrop | Seroquel | Seroquel xr | Setinin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Neutapin | Quantia | Quapine | Seroquel xr | Squro</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Quetap | Seroquel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ankep | Cedrina | Cedrina xr | Etipin | Gyrex | Keday xr | Ketilept | Ketinel | Ketya | Ketya xr | Quelept | Quet | Quet xr | Sequa | Serex | Seroquel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo quetiapine | Calm Ez | Calm relax | Hiloca | Limus | Megazon | Neuroquel | Q pine xr | Quelip xr | Quepine | Queropin | Quetia | Quetialin | Quetipine | Quiapine | Seroquel | Utapine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ketilept | Kventiax | Quetiapine darnitsa | Quetipin | Quetiron | Quetiron xr acino | Quetixol | Seroquel | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Asicot | Catepsin | Quetia | Quetiapina Noas | Quetiazic | Quetipax | Seroquel xr | Valir</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dropil | Edagan | Ketian | Letalop | Quetiapina | Quetiapina kern pharma | Quetiazic | Quetidin | Seroquel xr</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Daquetin | Morientes | Zitad</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aroquet | Dopaquel | Kizofrin | Mylan Quetiapine | Psyquet | Quetiapine mylan | Quetoser | Serez | Seroquel xr | Sizonorm | Spec quetiapine | Torquit | Truvalin | Zimbiquet</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Seroquel xr | Torquite sr</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16317314">
<a name="16317314"></a>Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. <i>Int Clin Psychopharmacol</i>. 2006;21(1):29-33. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16317314/pubmed" id="16317314" target="_blank">16317314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35582951">
<a name="35582951"></a>Ahmed A, Affleck AG, Angus J, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of adults with delusional infestation 2022. <i>Br J Dermatol.</i> 2022;187(4):472-480. doi:10.1111/bjd.21668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/35582951/pubmed" id="35582951" target="_blank">35582951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16808551">
<a name="16808551"></a>Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? <i>Drug Saf</i>. 2006;29(7):587-598. doi:10.2165/00002018-200629070-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16808551/pubmed" id="16808551" target="_blank">16808551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29197846">
<a name="29197846"></a>Ajayi OO, Holroyd S. Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy. <i>BMJ Case Rep</i>. 2017;2017:bcr2017222462. doi:10.1136/bcr-2017-222462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/29197846/pubmed" id="29197846" target="_blank">29197846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24987947">
<a name="24987947"></a>Alastal Y, Hasan S, Chowdhury MA, et al. Hypertriglyceridemia-induced pancreatitis in psychiatric patients: a case report and review of literature. <i>Am J Ther</i>. 2016;23(3):e947-e949. doi:10.1097/MJT.0000000000000101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24987947/pubmed" id="24987947" target="_blank">24987947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34745700">
<a name="34745700"></a>Aljabari S, Carter C, Waheed S, Anderson JE. Practice variability in screening and treating pediatric critical illness delirium: survey. <i>J Pediatr Intensive</i>
<i>Care</i>. 2020;10(4):271-275. doi:10.1055/s-0040-1716579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/34745700/pubmed" id="34745700" target="_blank">34745700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31481872">
<a name="31481872"></a>Almeida F, Albuquerque E, Murta I. Delirium induced by quetiapine and the potential role of norquetiapine. <i>Front Neurosci</i>. 2019;13:886. doi:10.3389/fnins.2019.00886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31481872/pubmed" id="31481872" target="_blank">31481872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31524318">
<a name="31524318"></a>Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. <i>Obes Rev</i>. 2019;20(12):1680-1690. doi:10.1111/obr.12934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31524318/pubmed" id="31524318" target="_blank">31524318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21403524">
<a name="21403524"></a>Altamura AC, Serati M, Buoli M, Dell'Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. <i>Int Clin Psychopharmacol</i>. 2011;26(4):201-205. doi:10.1097/YIC.0b013e3283457d73<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21403524/pubmed" id="21403524" target="_blank">21403524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists. ACOG practice bulletin: clinical management guidelines for obstetricians-gynecologists No. 92 April 2008 (replaces practice bulletin Number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14981231">
<a name="14981231"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Obes Res</i>. 2004;12(2):362-368. doi:10.1038/oby.2004.46<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14981231/pubmed" id="14981231" target="_blank">14981231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272. doi:10.4088/jcp.v65n0219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Diabetes Care</i>. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30375086">
<a name="30375086"></a>Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. <i>Psychiatry Clin Neurosci</i>. 2019;73(1):27-33. doi:10.1111/pcn.12793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/30375086/pubmed" id="30375086" target="_blank">30375086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30466224">
<a name="30466224"></a>Arıcı A, Altun H, Acıpayam C. Quetiapine induced autoimmune hemolytic anemia in a child patient: A case report. <i>Clin Psychopharmacol Neurosci</i>. 2018;16(4):501-504. doi:10.9758/cpn.2018.16.4.501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/30466224/pubmed" id="30466224" target="_blank">30466224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794516">
<a name="18794516"></a>Armstrong D, Ahuja N, Lloyd AJ. Quetiapine-related dysphagia. <i>Psychosomatics</i>. 2008;49(5):450-452. doi:10.1176/appi.psy.49.5.450-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18794516/pubmed" id="18794516" target="_blank">18794516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arslan.2016">
<a name="Arslan.2016"></a>Arslan FC, Aykut DS, Tiryaki A. Neutropenia and thrombocytopenia induced by quetiapine monotherapy: A case report and review of literature. <i>Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology</i>. 2016;26:3, 319-323. doi:10.5455/bcp.20151219072235</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33328024">
<a name="33328024"></a>Aruachán S, Morales S, Caicedo SM. Hyponatraemia associated with the use of quetiapine: case report. <i>Rev Colomb Psiquiatr (Engl Ed)</i>. 2020;49(4):297-300. doi:10.1016/j.rcp.2019.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/33328024/pubmed" id="33328024" target="_blank">33328024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11981352">
<a name="11981352"></a>Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment-resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. <i>Int Clin Psychopharmacol</i>. 2002;17(3):115-119. doi:10.1097/00004850-200205000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11981352/pubmed" id="11981352" target="_blank">11981352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18338766">
<a name="18338766"></a>Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. <i>Hum Psychopharmacol</i>. 2008;23(3):201-209. doi:10.1002/hup.924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18338766/pubmed" id="18338766" target="_blank">18338766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19691907">
<a name="19691907"></a>Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. <i>Int J Neuropsychopharmacol</i>. 2010;13(3):305-320. doi:10.1017/S1461145709990423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19691907/pubmed" id="19691907" target="_blank">19691907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22540422">
<a name="22540422"></a>Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>Int J Psychiatry Clin Pract</i>. 2012;16(2):77-84. doi:10.3109/13651501.2012.667114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22540422/pubmed" id="22540422" target="_blank">22540422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beach.2013">
<a name="Beach.2013"></a>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc Prolongation, torsades de pointes, and psychotropic medications. <i>Psychosomatics</i>. 2013:54;1-13.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benedek.2009">
<a name="Benedek.2009"></a>Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: American Psychiatric Association; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21494344">
<a name="21494344"></a>Bharadwaj RS, Slade TB. Sustained hypotension with initial low dose of quetiapine in a middle-aged man receiving an antihypertensive agent. <i>Prim Care Companion J Clin Psychiatry</i>. 2010;12(6):PCC.10l00981. doi:10.4088/PCC.10l00981yel<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21494344/pubmed" id="21494344" target="_blank">21494344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953514">
<a name="28953514"></a>Bhogal S, Ladia V, Paul TK. Quetiapine-associated myopericarditis. <i>Am J Ther</i>. 2018;25(5):e578-e579. doi:10.1097/MJT.0000000000000671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28953514/pubmed" id="28953514" target="_blank">28953514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958039">
<a name="19958039"></a>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. <i>CNS Drugs</i>. 2009;23(12):1003-1021. doi:10.2165/11530020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19958039/pubmed" id="19958039" target="_blank">19958039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16282853">
<a name="16282853"></a>Blasco-Fontecilla H, Bragado Jiménez MD, García Santos LM, Barjau Romero JM. Delusional disorder with delusions of parasitosis and jealousy after stroke: treatment with quetiapine and sertraline. <i>J Clin Psychopharmacol</i>. 2005;25(6):615-617. doi:10.1097/01.jcp.0000185344.39849.63<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16282853/pubmed" id="16282853" target="_blank">16282853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12623765">
<a name="12623765"></a>Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. <i>J Sex Marital Ther</i>. 2003;29(2):125-147. doi:10.1080/713847170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12623765/pubmed" id="12623765" target="_blank">12623765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shelton.2019">
<a name="Shelton.2019"></a>Bobo WV, Shelton RC. Bipolar major depression in adults: Efficacy and adverse effects of antidepressants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36587739">
<a name="36587739"></a>Borgsteede SD, Metselaar HJ, Mulder MB. Safety of antipsychotics and dose recommendations in patients with cirrhosis from a pharmacological perspective. <i>J Acad Consult Liaison Psychiatry</i>. 2023;64(3):316-317. doi:10.1016/j.jaclp.2022.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/36587739/pubmed" id="36587739" target="_blank">36587739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25363460">
<a name="25363460"></a>Bozat-Emre S, Doupe M, Kozyrskyj AL, Grymonpre R, Mahmud SM. Atypical antipsychotic drug use and falls among nursing home residents in Winnipeg, Canada. <i>Int J Geriatr Psychiatry</i>. 2015;30(8):842-850. doi:10.1002/gps.4223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25363460/pubmed" id="25363460" target="_blank">25363460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26908691">
<a name="26908691"></a>Brahmbhatt K, Whitgob E. Diagnosis and management of delirium in critically ill infants: case report and review. <i>Pediatrics</i>. 2016;137(3):e20151940. doi:10.1542/peds.2015-1940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26908691/pubmed" id="26908691" target="_blank">26908691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15672600">
<a name="15672600"></a>Byerly MJ, Lescouflair E, Weber MT, et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. <i>J Sex Marital Ther</i>. 2004;30(5):325-332. doi:10.1080/00926230490465082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15672600/pubmed" id="15672600" target="_blank">15672600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;(65)(suppl 7):4-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi:10.1007/s40263-013-0079-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tarsy.2019">
<a name="Tarsy.2019"></a>Chahine L. Management of nonmotor symptoms in Parkinson disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21808723">
<a name="21808723"></a>Chakrabarti S. Thyroid functions and bipolar affective disorder. <i>J Thyroid Res</i>. 2011;2011:306367. doi:10.4061/2011/306367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21808723/pubmed" id="21808723" target="_blank">21808723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18752690">
<a name="18752690"></a>Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. <i>BMC Psychiatry</i>. 2008;8:73. doi:10.1186/1471-244X-8-73<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18752690/pubmed" id="18752690" target="_blank">18752690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27367744">
<a name="27367744"></a>Chatziralli IP, Peponis V, Parikakis E, et al. Risk factors for intraoperative floppy iris syndrome: a prospective study. <i>Eye (Lond)</i>. 2016;30(8):1039-1044. doi:10.1038/eye.2016.122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27367744/pubmed" id="27367744" target="_blank">27367744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27199530">
<a name="27199530"></a>Chen L, Tan P, Tan X. Case report of eosinophilia induced by quetiapine. <i>Shanghai Arch Psychiatry</i>. 2015;27(6):374-377. doi:10.3969/j.issn.1002-0829.215005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27199530/pubmed" id="27199530" target="_blank">27199530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16928430">
<a name="16928430"></a>Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. <i>Schizophr Res</i>. 2006;88(1-3):63-72. doi:10.1016/j.schres.2006.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16928430/pubmed" id="16928430" target="_blank">16928430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22107783">
<a name="22107783"></a>Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. <i>Int Clin Psychopharmacol</i>. 2012;27(2):76-90. doi:10.1097/YIC.0b013e32834e4c56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22107783/pubmed" id="22107783" target="_blank">22107783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27061658">
<a name="27061658"></a>Chou PH, Chu CS, Lin CH, et al. Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: a population-based, nested case-control study. <i>Schizophr Res</i>. 2016;174(1-3):137-143. doi:10.1016/j.schres.2016.03.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27061658/pubmed" id="27061658" target="_blank">27061658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27855291">
<a name="27855291"></a>Chou RH, Lo LW, Liou YJ, et al. Antipsychotic treatment is associated with risk of atrial fibrillation: a nationwide nested case-control study. <i>Int J Cardiol</i>. 2017;227:134-140. doi:10.1016/j.ijcard.2016.11.185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27855291/pubmed" id="27855291" target="_blank">27855291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25580921">
<a name="25580921"></a>Christodoulou C, Margaritis D, Makris G, et al. Quetiapine and clarithromycin-induced neuroleptic malignant syndrome. <i>Clin Neuropharmacol</i>. 2015;38(1):36-37. doi:10.1097/WNF.0000000000000060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25580921/pubmed" id="25580921" target="_blank">25580921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28141623">
<a name="28141623"></a>Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: Absolute risk increase and number needed to harm. <i>J Clin Psychopharmacol</i>. 2017;37(2):138-147. doi:10.1097/JCP.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28141623/pubmed" id="28141623" target="_blank">28141623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21946883">
<a name="21946883"></a>Coffey S, Williams M. Quetiapine-associated cardiomyopathy. <i>N Z Med J</i>. 2011;124(1337):105-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21946883/pubmed" id="21946883" target="_blank">21946883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533766">
<a name="18533766"></a>Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>J Clin Psychiatry</i>. 2008;69(suppl 4):26-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18533766/pubmed" id="18533766" target="_blank">18533766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19861668">
<a name="19861668"></a>Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. <i>JAMA.</i> 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19861668/pubmed" id="19861668" target="_blank">19861668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16930797">
<a name="16930797"></a>Cowan C, Oakley C. Leukopenia and neutropenia induced by quetiapine. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2007;31(1):292-294. doi:10.1016/j.pnpbp.2006.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16930797/pubmed" id="16930797" target="_blank">16930797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26237252">
<a name="26237252"></a>Cox JH, Seri S, Cavanna AE. Clinical guidelines on long-term pharmacotherapy for bipolar disorder in children and adolescents. <i>J Clin Med</i>. 2014;3(1):135-143. doi:10.3390/jcm3010135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26237252/pubmed" id="26237252" target="_blank">26237252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.2019">
<a name="Craske.2019"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11496032">
<a name="11496032"></a>Croarkin P, Rayner T. Acute neutropenia in a patient treated with quetiapine. <i>Psychosomatics</i>. 2001;42(4):368. doi:10.1176/appi.psy.42.4.368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11496032/pubmed" id="11496032" target="_blank">11496032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18572981">
<a name="18572981"></a>Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. <i>J Clin Psychiatry</i>. 2008;69(7):1157-1165. doi:10.4088/jcp.v69n0716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18572981/pubmed" id="18572981" target="_blank">18572981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33634425">
<a name="33634425"></a>Cronin MT, Di Gennaro JL, Watson RS, Dervan LA. Haloperidol and quetiapine for the treatment of ICU-associated delirium in a tertiary pediatric ICU: a propensity score-matched cohort study. <i>Paediatr Drugs</i>. 2021;23(2):159-169. doi:10.1007/s40272-021-00437-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/33634425/pubmed" id="33634425" target="_blank">33634425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: A case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19638254">
<a name="19638254"></a>Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. <i>Int J Neuropsychopharmacol</i>. 2010;13(1):5-14. doi:10.1017/S1461145709990344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19638254/pubmed" id="19638254" target="_blank">19638254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12504073">
<a name="12504073"></a>Cutler AJ. Sexual dysfunction and antipsychotic treatment. <i>Psychoneuroendocrinology</i>. 2003;(28 suppl 1):69-82. doi:10.1016/s0306-4530(02)00113-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12504073/pubmed" id="12504073" target="_blank">12504073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28786826">
<a name="28786826"></a>Das A, Guarda LA, Allen LG. Liver Injury associated with auetiapine: an illustrative case Rrport. <i>J Clin Psychopharmacol</i>. 2017;37(5):623-625. doi:10.1097/JCP.0000000000000749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28786826/pubmed" id="28786826" target="_blank">28786826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12364843">
<a name="12364843"></a>Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. <i>J Am Acad Child Adolesc Psychiatry</i>. 2002;41(10):1216-1223. doi:10.1097/00004583-200210000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12364843/pubmed" id="12364843" target="_blank">12364843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15323587">
<a name="15323587"></a>Denys D, de Geus F, van Megen HG, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. <i>J Clin Psychiatry</i>. 2004;65(8):1040-1048. doi:10.4088/jcp.v65n0803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15323587/pubmed" id="15323587" target="_blank">15323587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11510628">
<a name="11510628"></a>DeVane CL and Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. <i>Clin Pharmacokinet.</i> 2001;40(7):509-522. doi:10.2165/00003088-200140070-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11510628/pubmed" id="11510628" target="_blank">11510628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19915454">
<a name="19915454"></a>Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. <i>Crit Care Med.</i> 2010;38(2):419-427. doi:10.1097/CCM.0b013e3181b9e302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19915454/pubmed" id="19915454" target="_blank">19915454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22932229">
<a name="22932229"></a>Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. <i>Int J Neuropsychopharmacol</i>. 2013;16(3):557-574. doi:10.1017/S1461145712000740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22932229/pubmed" id="22932229" target="_blank">22932229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590213">
<a name="25590213"></a>Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2015;100(2):363-370. doi:10.1210/jc.2014-3421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25590213/pubmed" id="25590213" target="_blank">25590213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dsouza.2020">
<a name="Dsouza.2020"></a>D'Souza RS, Hooten WM. Extrapyramidal symptoms (EPS). NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. 2020. <a href="https://www.ncbi.nlm.nih.gov/books/NBK534115/?report=printable" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK534115/?report=printable</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30531242">
<a name="30531242"></a>Elkhouly MA, Salazar MJ, Simons-Linares CR. Hypertriglyceridemia-associated drug-induced acute pancreatitis. <i>Pancreas</i>. 2019;48(1):22-35. doi:10.1097/MPA.0000000000001190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/30531242/pubmed" id="30531242" target="_blank">30531242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26813985">
<a name="26813985"></a>El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. <i>J Clin Pharm Ther</i>. 2016;41(1):7-18. doi:10.1111/jcpt.12357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26813985/pubmed" id="26813985" target="_blank">26813985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278567">
<a name="23278567"></a>Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. <i>J Forensic Sci</i>. 2013;58(2):398-403. doi:10.1111/1556-4029.12044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23278567/pubmed" id="23278567" target="_blank">23278567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15163258">
<a name="15163258"></a>Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. <i>J Clin Psychiatry</i>. 2004;65(5):696-701. doi:10.4088/jcp.v65n0516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15163258/pubmed" id="15163258" target="_blank">15163258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25948288">
<a name="25948288"></a>Fan KY, Chen WY, Huang MC. Quetiapine-associated leucopenia and thrombocytopenia: a case report. <i>BMC Psychiatry</i>. 2015;15:110. doi:10.1186/s12888-015-0495-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25948288/pubmed" id="25948288" target="_blank">25948288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10772436">
<a name="10772436"></a>Feret BM, Caley CF. Possible hypothyroidism associated with quetiapine. <i>Ann Pharmacother</i>. 2000;34(4):483-486. doi:10.1345/aph.19186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10772436/pubmed" id="10772436" target="_blank">10772436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10348474">
<a name="10348474"></a>Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. <i>Mov Disord</i>. 1999;14(3):484-487. doi:10.1002/1531-8257(199905)14:3&lt;484::aid-mds1016&gt;3.0.co;2-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10348474/pubmed" id="10348474" target="_blank">10348474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19916848">
<a name="19916848"></a>Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. <i>Int J Neurosci</i>. 2009;119(12):2196-2205. doi:10.3109/00207450903222758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19916848/pubmed" id="19916848" target="_blank">19916848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23279439">
<a name="23279439"></a>Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. <i>Eur J Neurol</i>. 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23279439/pubmed" id="23279439" target="_blank">23279439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15933483">
<a name="15933483"></a>Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. <i>Int Clin Psychopharmacol</i>. 2005;20(4):223-226. doi:10.1097/00004850-200507000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15933483/pubmed" id="15933483" target="_blank">15933483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24956042">
<a name="24956042"></a>Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. <i>J Child Adolesc Psychopharmacol</i>. 2014;24(6):325-335. doi:10.1089/cap.2013.0105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24956042/pubmed" id="24956042" target="_blank">24956042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23(suppl 1):27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25581312">
<a name="25581312"></a>Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. <i>JAMA Intern Med</i>. 2015;175(3):450-452. doi:10.1001/jamainternmed.2014.6930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25581312/pubmed" id="25581312" target="_blank">25581312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15531330">
<a name="15531330"></a>Fraunfelder FW. Twice-yearly exams unnecessary for patients taking quetiapine. <i>Am J Ophthalmol</i>. 2004;138(5):870-871. doi:10.1016/j.ajo.2004.05.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15531330/pubmed" id="15531330" target="_blank">15531330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794644">
<a name="18794644"></a>Freudenmann RW, Lepping P. Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy. <i>J Clin Psychopharmacol</i>. 2008;28(5):500-508. doi:10.1097/JCP.0b013e318185e774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18794644/pubmed" id="18794644" target="_blank">18794644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15118358">
<a name="15118358"></a>Fujikawa T, Takahashi T, Kinoshita A, et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. <i>Neuropsychobiology</i>. 2004;49(4):201-204. doi:10.1159/000077367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15118358/pubmed" id="15118358" target="_blank">15118358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11839370">
<a name="11839370"></a>Furst BA, Champion KM, Pierre JM, Wirshing DA, Wirshing WC. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. <i>Biol Psychiatry</i>. 2002;51(3):264-265. doi:10.1016/s0006-3223(01)01333-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11839370/pubmed" id="11839370" target="_blank">11839370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15816805">
<a name="15816805"></a>Galynker I, Khan A, Grebchenko Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. <i>J Clin Psychiatry</i>. 2005;66(4):544. doi:10.4088/jcp.v66n0420f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15816805/pubmed" id="15816805" target="_blank">15816805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18344731">
<a name="18344731"></a>Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. <i>J Clin Psychopharmacol</i>. 2008;28(2):203-209. doi:10.1097/JCP.0b013e318166c4d5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18344731/pubmed" id="18344731" target="_blank">18344731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gedam.2015">
<a name="Gedam.2015"></a>Gedam SR, Ghosh S. Acute dystonia induced by quetiapine: a case report. <i>Open J Psychiatry Allied</i>. 2015;6(1):59-61.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28796018">
<a name="28796018"></a>Glocker C, Grohmann R, Schulz H. Fatal agranulocytosis associated with quetiapine in monotherapy: A case report. <i>J Clin Psychopharmacol</i>. 2017;37(5):625-627. doi:10.1097/JCP.0000000000000752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28796018/pubmed" id="28796018" target="_blank">28796018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29983780">
<a name="29983780"></a>Gorup E, Rifel J, Petek Šter M. Anticholinergic burden and most common anticholinergic-acting medicines in older general practice patients. <i>Zdr Varst</i>. 2018;57(3):140-147. doi:10.2478/sjph-2018-0018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/29983780/pubmed" id="29983780" target="_blank">29983780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26908706">
<a name="26908706"></a>Groves A, Traube C, Silver G. Detection and management of delirium in the neonatal unit: a case series. <i>Pediatrics</i>. 2016;137(3):e20153369. doi:10.1542/peds.2015-3369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26908706/pubmed" id="26908706" target="_blank">26908706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36180017">
<a name="36180017"></a>Gunther M, Dopheide JA. Antipsychotic safety in liver disease: a narrative review and practical guide for the clinician. <i>J Acad Consult Liaison Psychiatry.</i> 2023;64(1):73-82. doi:10.1016/j.jaclp.2022.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/36180017/pubmed" id="36180017" target="_blank">36180017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22057019">
<a name="22057019"></a>Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. <i>J Psychopharmacol</i>. 2012;26(5 suppl):15-26. doi:10.1177/0269881111424929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22057019/pubmed" id="22057019" target="_blank">22057019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15618854">
<a name="15618854"></a>Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. <i>Eur J Gastroenterol Hepatol</i>. 2004;16(12):1415-1418. doi:10.1097/00042737-200412000-00029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15618854/pubmed" id="15618854" target="_blank">15618854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12544370">
<a name="12544370"></a>Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. <i>J Clin Psychopharmacol</i>. 2003;23(1):15-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12544370/pubmed" id="12544370" target="_blank">12544370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709949">
<a name="14709949"></a>Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. <i>J Clin Psychopharmacol</i>. 2004;24(1):62-69. doi:10.1097/01.jcp.0000104913.75206.62<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14709949/pubmed" id="14709949" target="_blank">14709949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25168784">
<a name="25168784"></a>Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. <i>CNS Drugs</i>. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25168784/pubmed" id="25168784" target="_blank">25168784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthyCanadians.2018">
<a name="HealthyCanadians.2018"></a>Healthy Canadians Recalls &amp; Alerts: Summary safety review - atypical antipsychotics - assessing the potential risk of drug reaction with eosinophilia and systemic symptoms (DRESS). Health Canada website. <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-drug-reaction-eosinophilia-systemic-symptoms.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-drug-reaction-eosinophilia-systemic-symptoms.html</a>. Published April 10, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthyCanadians.2016">
<a name="HealthyCanadians.2016"></a>Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. Available at: <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html</a>. Published August 16, 2016. Accessed August 23, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789596">
<a name="23789596"></a>Heller MM, Wong JW, Lee ES, et al. Delusional infestations: clinical presentation, diagnosis and treatment. <i>Int J Dermatol</i>. 2013;52(7):775-783. doi:10.1111/ijd.12067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23789596/pubmed" id="23789596" target="_blank">23789596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12424166">
<a name="12424166"></a>Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. <i>BMJ</i>. 2002;325(7372):1070. doi:10.1136/bmj.325.7372.1070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12424166/pubmed" id="12424166" target="_blank">12424166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW,et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21733490">
<a name="21733490"></a>Honer WG, MacEwan GW, Gendron A, et al; STACK Study Group. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. <i>J Clin Psychiatry</i>. 2012;73(1):13-20. doi:10.4088/JCP.10m06194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21733490/pubmed" id="21733490" target="_blank">21733490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-825191509">
<a name="825191509"></a>Hou YC, Lai CH. Late-onset quetiapine-related tardive dyskinesia side effects in a patient with psychotic depression. <i>Clin Psychopharmacol Neurosci</i>. 2014;12(2):163-165. doi:10.9758/cpn.2014.12.2.163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25191509/pubmed" id="25191509" target="_blank">25191509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV; The International Late-Onset Schizophrenia Group. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22561472">
<a name="22561472"></a>Hung WC, Hsieh MH. Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients. <i>J Clin Psychopharmacol</i>. 2012;32(3):416-417. doi:10.1097/JCP.0b013e3182549d2d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22561472/pubmed" id="22561472" target="_blank">22561472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27340908">
<a name="27340908"></a>Husnain M, Gondal F, Raina AI, Riaz IB, Anwer F. Quetiapine associated thrombotic thrombocytopenic purpura: A case report and literature review. <i>Am J Ther</i>. 2017;24(5):e615-e616. doi:10.1097/MJT.0000000000000456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27340908/pubmed" id="27340908" target="_blank">27340908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15914516">
<a name="15914516"></a>Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. <i>Ann Pharmacother</i>. 2005;39(7-8):1346-1348. doi:10.1345/aph.1G067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15914516/pubmed" id="15914516" target="_blank">15914516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288069">
<a name="21288069"></a>Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and Other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World J Biol Psychiatry</i>. 2011;12(1):2-32. doi:10.3109/15622975.2010.538083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21288069/pubmed" id="21288069" target="_blank">21288069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14743357">
<a name="14743357"></a>Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. <i>Mov Disord</i>. 2004;19(1):29-35. doi:10.1002/mds.10620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14743357/pubmed" id="14743357" target="_blank">14743357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kales.2012">
<a name="Kales.2012"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18025545">
<a name="18025545"></a>Kao RL, Kelly LM. Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine. <i>Can J Clin Pharmacol</i>. 2007;14(3):e322-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18025545/pubmed" id="18025545" target="_blank">18025545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23567397">
<a name="23567397"></a>Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. <i>Am J Geriatr Psychiatry</i>. 2013;21(8):769-784. doi:10.1016/j.jagp.2013.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23567397/pubmed" id="23567397" target="_blank">23567397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des Troubles Anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):s1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20881846">
<a name="20881846"></a>Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.<i> Int Clin Psychopharmacol</i>. 2011;26(1):11-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20881846/pubmed" id="20881846" target="_blank">20881846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13679531">
<a name="13679531"></a>Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children.<i> N Engl J Med</i>. 2003;349(12):1157-1167. doi:10.1056/NEJMra035092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/13679531/pubmed" id="13679531" target="_blank">13679531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15954189">
<a name="15954189"></a>Kelly DL, Conley RR. Sexuality and schizophrenia: a review. <i>Schizophr Bull</i>. 2004;30(4):767-779. doi:10.1093/oxfordjournals.schbul.a007130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15954189/pubmed" id="15954189" target="_blank">15954189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15669892">
<a name="15669892"></a>Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. <i>J Clin Psychiatry</i>. 2005;66(1):80-84. doi:10.4088/jcp.v66n0111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15669892/pubmed" id="15669892" target="_blank">15669892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24199224">
<a name="24199224"></a>Khan A, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study. <i>Ann Clin Psychiatry</i>. 2013;25(4):E7-E22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24199224/pubmed" id="24199224" target="_blank">24199224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21694613">
<a name="21694613"></a>Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. <i>J Clin Psychopharmacol</i>. 2011;31(4):418-428. doi:10.1097/JCP.0b013e318224864d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21694613/pubmed" id="21694613" target="_blank">21694613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26950553">
<a name="26950553"></a>Kim A, Lim KS, Lee H, et al. A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. <i>Int Clin Psychopharmacol</i>. 2016;31(4):210-217. doi:10.1097/YIC.0000000000000124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26950553/pubmed" id="26950553" target="_blank">26950553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31059621">
<a name="31059621"></a>Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. <i>World Psychiatry</i>. 2019;18(2):208-224. doi:10.1002/wps.20632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31059621/pubmed" id="31059621" target="_blank">31059621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18615368">
<a name="18615368"></a>Kohen I, Lester P. Quetiapine-associated dysphagia. <i>World J Biol Psychiatry</i>. 2009;10(4 Pt 2):623-625. doi:10.1080/15622970802176495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18615368/pubmed" id="18615368" target="_blank">18615368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12176106">
<a name="12176106"></a>Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. <i>Eur J Pharmacol</i>. 2002;450(1):37-41. doi:10.1016/s0014-2999(02)02074-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12176106/pubmed" id="12176106" target="_blank">12176106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19820433">
<a name="19820433"></a>Kontaxakis VP, Karaiskos D, Havaki-Kontaxaki BJ, Ferentinos P, Papadimitriou GN. Can quetiapine-induced hypothyroidism be reversible without quetiapine discontinuation?. <i>Clin Neuropharmacol</i>. 2009;32(5):295-296. doi:10.1097/WNF.0b013e3181a8cbcc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19820433/pubmed" id="19820433" target="_blank">19820433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146612">
<a name="28146612"></a>Koponen M, Taipale H, Lavikainen P, et al. Antipsychotic use and the risk of hip fracture among community-dwelling persons with Alzheimer's disease. <i>J Clin Psychiatry</i>. 2017;78(3):e257-e263. doi:10.4088/JCP.15m10458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28146612/pubmed" id="28146612" target="_blank">28146612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849776">
<a name="17849776"></a>Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>Am J Psychiatry</i>. 2007;164(7)(suppl):5-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17849776/pubmed" id="17849776" target="_blank">17849776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15869022">
<a name="15869022"></a>Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. <i>Essent Psychopharmacol</i>. 2005;6(3):148-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15869022/pubmed" id="15869022" target="_blank">15869022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27034875">
<a name="27034875"></a>Koufakis T. Quetiapine-induced syndrome of inappropriate secretion of antidiuretic hormone. <i>Case Rep Psychiatry</i>. 2016;2016:4803132. doi:10.1155/2016/4803132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27034875/pubmed" id="27034875" target="_blank">27034875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16945162">
<a name="16945162"></a>Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. <i>Int J Neuropsychopharmacol</i>. 2007;10(2):253-261. doi:10.1017/S1461145706006596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16945162/pubmed" id="16945162" target="_blank">16945162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21058927">
<a name="21058927"></a>Lander M, Bastiampillai T. Neutropenia associated with quetiapine, olanzapine, and aripiprazole. <i>Aust N Z J Psychiatry</i>. 2011;45(1):89. doi:10.3109/00048674.2010.524624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21058927/pubmed" id="21058927" target="_blank">21058927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Landau.2008">
<a name="Landau.2008"></a>Landau J, Lue K, Cheng C, Greenberg P. Medical mishap. <i>Australian Prescriber</i>. 2008;31(1):10.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23470612">
<a name="23470612"></a>Lasić D, Ivanišević R, Uglešić B, Cvitanović MZ, Glučina D, Hlevnjak I. Acute generalized exanthematous pustulosis as a side effect of quetiapine. <i>Psychiatr Danub</i>. 2013;25(1):84-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23470612/pubmed" id="23470612" target="_blank">23470612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737244">
<a name="23737244"></a>La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. <i>Pharmacopsychiatry</i>. 2013;46(6):201-208. doi:10.1055/s-0033-1347177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23737244/pubmed" id="23737244" target="_blank">23737244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15337669">
<a name="15337669"></a>Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. <i>Am J Psychiatry</i>. 2004;161(9):1715-1716. doi:10.1176/appi.ajp.161.9.1715-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15337669/pubmed" id="15337669" target="_blank">15337669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. <i>Schizophr Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33060431">
<a name="33060431"></a>Li T, Wang Y, Li W, et al. Quetiapine-associated rhabdomyolysis: a case report and literature review. <i>J Clin Psychopharmacol</i>. 2020;40(6):619-624. doi:10.1097/JCP.0000000000001292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/33060431/pubmed" id="33060431" target="_blank">33060431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21346616">
<a name="21346616"></a>Lindenmayer JP, Citrome L, Khan A, Kaushik S, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. <i>J Clin Psychopharmacol</i>. 2011;31(2):160-168. doi:10.1097/JCP.0b013e31820f4fe0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21346616/pubmed" id="21346616" target="_blank">21346616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24719155">
<a name="24719155"></a>Liou LS, Hung YJ, Hsieh CH, Hsiao FC. Aggravation of hypertriglyceridemia and acute pancreatitis in a bipolar patient treated with quetiapine. <i>Yonsei Med J</i>. 2014;55(3):831-833. doi:10.3349/ymj.2014.55.3.831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24719155/pubmed" id="24719155" target="_blank">24719155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16633154">
<a name="16633154"></a>Liappas J, Paparrigopoulos T, Mourikis I, Soldatos C. Hypothyroidism induced by quetiapine: a case report. <i>J Clin Psychopharmacol</i>. 2006;26(2):208-209. doi:10.1097/01.jcp.0000203227.56494.ff<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16633154/pubmed" id="16633154" target="_blank">16633154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24062697">
<a name="24062697"></a>López-Muñoz F, Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. <i>Front Psychiatry</i>. 2013;4:102. doi:10.3389/fpsyt.2013.00102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24062697/pubmed" id="24062697" target="_blank">24062697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maan.2020">
<a name="Maan.2020"></a>Maan JS, Saadabadi A. Quetiapine. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. 2020. <a href="https://www.ncbi.nlm.nih.gov/books/NBK459145/?report=printable" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK459145/?report=printable</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24403385">
<a name="24403385"></a>Madsen KR. Fatal hypertriglyceridaemia, acute pancreatitis and diabetic ketoacidosis possibly induced by quetiapine. <i>BMJ Case Rep</i>. 2014;2014:bcr2013202039. doi:10.1136/bcr-2013-202039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24403385/pubmed" id="24403385" target="_blank">24403385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15090935">
<a name="15090935"></a>Mancini F, Tassorelli C, Martignoni E, et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. <i>Clin Neuropharmacol</i>. 2004;27(1):33-37. doi:10.1097/00002826-200401000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15090935/pubmed" id="15090935" target="_blank">15090935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23017200">
<a name="23017200"></a>Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. <i>BMC Psychiatry</i>. 2012;12:160. doi:10.1186/1471-244X-12-160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23017200/pubmed" id="23017200" target="_blank">23017200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26834458">
<a name="26834458"></a>Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. <i>Drug Des Devel Ther</i>. 2016;10:259-276. doi:10.2147/DDDT.S89485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26834458/pubmed" id="26834458" target="_blank">26834458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125. doi:10.1097/01.chi.0000242240.69678.c4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972700">
<a name="23972700"></a>McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23972700/pubmed" id="23972700" target="_blank">23972700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10830145">
<a name="10830145"></a>McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine rumarate: An open-label trial in adolescents with psychotic disorders. <i>J Clin Psychiatry.</i> 2000;61(4):252-260. doi:10.4088/jcp.v61n0403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10830145/pubmed" id="10830145" target="_blank">10830145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17177199">
<a name="17177199"></a>McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. <i>Depress Anxiety</i>. 2007;24(7):487-494. doi:10.1002/da.20275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17177199/pubmed" id="17177199" target="_blank">17177199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10362435">
<a name="10362435"></a>McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. <i>J Clin Psychiatry</i>. 1999;60(5):292-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10362435/pubmed" id="10362435" target="_blank">10362435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27522397">
<a name="27522397"></a>Melada A, Krčmar T, Vidović A. A dose-dependent relationship between quetiapine and QTc interval. <i>Int J Cardiol</i>. 2016;222:893-894. doi:10.1016/j.ijcard.2016.08.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27522397/pubmed" id="27522397" target="_blank">27522397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15025545">
<a name="15025545"></a>Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. <i>Drugs</i>. 2004;64(7):701-723. doi:10.2165/00003495-200464070-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15025545/pubmed" id="15025545" target="_blank">15025545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22045039">
<a name="22045039"></a>Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. <i>Int Clin Psychopharmacol</i>. 2012;27(1):40-54. doi:10.1097/YIC.0b013e32834d9f49<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22045039/pubmed" id="22045039" target="_blank">22045039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17095896">
<a name="17095896"></a>Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. <i>Clin Neuropharmacol</i>. 2006;29(6):331-337. doi:10.1097/01.WNF.0000236769.31279.19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17095896/pubmed" id="17095896" target="_blank">17095896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23070803">
<a name="23070803"></a>Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. <i>Int J Geriatr Psychiatry.</i> 2013;28(6):615-625. doi:10.1002/gps.3867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23070803/pubmed" id="23070803" target="_blank">23070803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18836354">
<a name="18836354"></a>Milia A, Mascia MG, Pilia G, et al. Efficacy and safety of quetiapine treatment for delusional parasitosis: experience in an elderly patient. <i>Clin Neuropharmacol</i>. 2008;31(5):310-312. doi:10.1097/WNF.0b013e3181587ce4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18836354/pubmed" id="18836354" target="_blank">18836354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. 2020;10:2045125320937910. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12548358">
<a name="12548358"></a>Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. <i>Neurol Sci</i>. 2002;23(suppl 2):S89-S90. doi:10.1007/s100720200084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12548358/pubmed" id="12548358" target="_blank">12548358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319699">
<a name="15319699"></a>Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. <i>Clin Neuropharmacol</i>. 2004;27(4):153-156. doi:10.1097/01.wnf.0000136891.17006.ec<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15319699/pubmed" id="15319699" target="_blank">15319699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morrato.2012">
<a name="Morrato.2012"></a>Morrato EH. An update on lipid profile screening in second-generation antipsychotic users in the USA. <i>Clinical Lipidology</i>. 2012;7(5):509-523.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11768836">
<a name="11768836"></a>Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. <i>Clin Ther</i>. 2001;23(11):1839-1854. doi:10.1016/s0149-2918(00)89080-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11768836/pubmed" id="11768836" target="_blank">11768836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20048451">
<a name="20048451"></a>Nagaraj AK, Pai NB, Rao S. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. <i>Indian J Psychiatry</i>. 2009;51(4):265-271. doi:10.4103/0019-5545.58291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20048451/pubmed" id="20048451" target="_blank">20048451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24945332">
<a name="24945332"></a>Nagy J. Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up. <i>Int J Psychiatry Clin Pract.</i> 2005;9(1):16-21. doi:10.1080/13651500510014765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24945332/pubmed" id="24945332" target="_blank">24945332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15765830">
<a name="15765830"></a>Nair P, Lippmann S. Blood dyscrasia with quetiapine and ziprasidone. <i>Psychosomatics</i>. 2005;46(1):89-90. doi:10.1176/appi.psy.46.1.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15765830/pubmed" id="15765830" target="_blank">15765830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nakamura.2016">
<a name="Nakamura.2016"></a>Nakamura M, Seki M, Sato Y, Nagamine T. Quetiapine-induced bradycardia and the hypotension in the elderly -- A case report. <i>Innov Clin Neurosci</i>. 2016;13(1-2):34-36.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28099349">
<a name="28099349"></a>Nanasawa H, Sako A, Mitsutsuka T, et al. Development of diabetes mellitus associated with quetiapine: a case series. <i>Medicine (Baltimore)</i>. 2017;96(3):e5900. doi:10.1097/MD.0000000000005900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28099349/pubmed" id="28099349" target="_blank">28099349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2">
<a name="NICE.2"></a>National Institute for Health and Clinical Excellence (NICE). Bipolar disorder. The NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. https://www.nice.org.uk/guidance/cg185/evidence/full-guideline-pdf-4840895629. Updated June 2022. Accessed September 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065063">
<a name="26065063"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. https://www.nice.org.uk/guidance/cg155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26065063/pubmed" id="26065063" target="_blank">26065063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113. Updated July 26, 2019. Accessed February 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.2018">
<a name="Nelson.2018"></a>Nelson C. Unipolar depression in adults: Treatment with second-generation antipsychotics. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Netherlands.2020">
<a name="Netherlands.2020"></a>Netherlands Pharmacovigilance Centre Lareb. Quetiapine and extrapyramidal effects. https://databankws.lareb.nl/Downloads/kwb_2006_1_queti.pdf. Published February 2006. Accessed August 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;19(suppl 1):1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17671284">
<a name="17671284"></a>Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. <i>Am J Psychiatry.</i> 2007;164(8):1214-1220. doi:10.1176/appi.ajp.2007.06111886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17671284/pubmed" id="17671284" target="_blank">17671284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20520598">
<a name="20520598"></a>Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i>. 2010;35(9):1997-2004. doi:10.1038/npp.2010.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20520598/pubmed" id="20520598" target="_blank">20520598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28291979">
<a name="28291979"></a>Ninčević Ž, Lasić D, Glavina T, Mikačić M, Carev M, Podrug K. Quetiapine poisoning associated with neuroleptic malignant syndrome, rhabdomyolysis and renal failure: A case report. <i>Psychiatr Danub</i>. 2017;29(1):84-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28291979/pubmed" id="28291979" target="_blank">28291979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22533871">
<a name="22533871"></a>Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. <i>J Sex Marital Ther</i>. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22533871/pubmed" id="22533871" target="_blank">22533871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012695">
<a name="17012695"></a>Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. <i>Am J Psychiatry</i>. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17012695/pubmed" id="17012695" target="_blank">17012695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635569">
<a name="12635569"></a>Oluboka O, Haslam D, Lam T, Bown-Demarco D. Quetiapine-induced leucopenia: possible dosage-related phenomenon. <i>Can J Psychiatry</i>. 2003;48(1):65-66. doi:10.1177/070674370304800116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12635569/pubmed" id="12635569" target="_blank">12635569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568278">
<a name="27568278"></a>Pacchiarotti I, León-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578. doi:10.1016/j.euroneuro.2016.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27568278/pubmed" id="27568278" target="_blank">27568278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16192842">
<a name="16192842"></a>Pae CU, Nassir Ghaemi S, Kim TS, et al. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial.<i> Int Clin Psychopharmacol.</i> 2005;20(6):327-330. doi:10.1097/00004850-200511000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16192842/pubmed" id="16192842" target="_blank">16192842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30484239">
<a name="30484239"></a>Pasina L, Colzani L, Cortesi L, et al. Relation between delirium and anticholinergic drug burden in a cohort of hospitalized older patients: An observational study. <i>Drugs Aging</i>. 2019;36(1):85-91. doi:10.1007/s40266-018-0612-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/30484239/pubmed" id="30484239" target="_blank">30484239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. Published 2019 Jul 20. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pelonero.1998">
<a name="Pelonero.1998"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatric Services</i> 1998;49:1163-1172.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24743712">
<a name="24743712"></a>Porcelli S, Balzarro B, de Ronchi D, Serretti A. Quetiapine extended release: preliminary evidence of a rapid onset of the antidepressant effect in bipolar depression. <i>J Clin Psychopharmacol</i>. 2014;34(3):303-306. doi:10.1097/JCP.0000000000000103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24743712/pubmed" id="24743712" target="_blank">24743712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.2019">
<a name="Post.2019"></a>Post R. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20614417">
<a name="20614417"></a>Poutanen O, Iso-Koivisto E, Työläjärvi M, Leinonen E. Quetiapine-associated hypothyroidism in young female patients: a report of three cases. <i>Pharmacopsychiatry</i>. 2010;43(6):237-239. doi:10.1055/s-0030-1261880<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/20614417/pubmed" id="20614417" target="_blank">20614417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Press.2019">
<a name="Press.2019"></a>Press D. Management of neuropsychiatric symptoms of dementia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19401471">
<a name="19401471"></a>Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. <i>Ann Pharmacother</i>. 2009;43(5):822-830. doi:10.1345/aph.1L617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19401471/pubmed" id="19401471" target="_blank">19401471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31571717">
<a name="31571717"></a>Ram D, Mathur S. Quetiapine-induced leukocytoclastic vasculitis. <i>Indian J Pharmacol</i>. 2019;51(4):282-283. doi:10.4103/ijp.IJP_680_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31571717/pubmed" id="31571717" target="_blank">31571717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15645000">
<a name="15645000"></a>Ramaswamy S, Siddiqui Z, Saharan S, Gabel TL, Bhatia SC. Quetiapine-induced hypothyroidism. <i>J Psychiatry Neurosci</i>. 2005;30(1):57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15645000/pubmed" id="15645000" target="_blank">15645000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17374621">
<a name="17374621"></a>Rampono J, Kristensen JH, Ilett KF, Hackett LP, Kohan R. Quetiapine and breast feeding. <i>Ann Pharmacother</i>. 2007;41(4):711-714. doi:10.1345/aph.1H555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17374621/pubmed" id="17374621" target="_blank">17374621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19724733">
<a name="19724733"></a>Rashid J, Starer PJ, Javaid S. Pancreatitis and diabetic ketoacidosis with quetiapine use. <i>Psychiatry (Edgmont)</i>. 2009;6(5):34-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19724733/pubmed" id="19724733" target="_blank">19724733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. doi:10.1176/appi.ajp.2015.173501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340682">
<a name="10340682"></a>Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;(60)(suppl 10):5-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10340682/pubmed" id="10340682" target="_blank">10340682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25844991">
<a name="25844991"></a>Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. <i>JAMA Pediatr</i>. 2015;169(4):e150285. doi:10.1001/jamapediatrics.2015.0285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25844991/pubmed" id="25844991" target="_blank">25844991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11722307">
<a name="11722307"></a>Ruhé HG, Becker HE, Jessurun P, Marees CH, Heeringa M, Vermeulen HD. Agranulocytosis and granulocytopenia associated with quetiapine. <i>Acta Psychiatr Scand</i>. 2001;104(4):311-314. doi:10.1034/j.1600-0447.2001.00429.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11722307/pubmed" id="11722307" target="_blank">11722307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sajatovic.2018">
<a name="Sajatovic.2018"></a>Sajatovic M, Chen P. Geriatric bipolar disorder: Acute treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25879993">
<a name="25879993"></a>Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. <i>BMC Geriatr</i>. 2015;15:31. doi:10.1186/s12877-015-0029-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25879993/pubmed" id="25879993" target="_blank">25879993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12040309">
<a name="12040309"></a>Scharre DW, Chang SI. cognitive and behavioral effects of quetiapine in Alzheimer disease patients. <i>Alzheimer Dis Assoc Disord</i>. 2002;16(2):128-130. doi:10.1097/00002093-200204000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12040309/pubmed" id="12040309" target="_blank">12040309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26132604">
<a name="26132604"></a>Schattner A, Kitroser E, Cohen JD. Fatal neuroleptic malignant syndrome associated with quetiapine. <i>Am J Ther</i>. 2016;23(5):e1209-e1210. doi:10.1097/MJT.0000000000000274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/26132604/pubmed" id="26132604" target="_blank">26132604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seroquel.2020.03">
<a name="Seroquel.2020.03"></a>Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SeroquelXR.2020.01">
<a name="SeroquelXR.2020.01"></a>Seroquel XR (quetiapine extended release) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21191308">
<a name="21191308"></a>Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>Int Clin Psychopharmacol</i>. 2011;26(3):130-140. doi:10.1097/YIC.0b013e328341e434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21191308/pubmed" id="21191308" target="_blank">21191308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21267374">
<a name="21267374"></a>Sethi S, Sharma M, Malik A. Dose-dependent galactorrhea with quetiapine. <i>Indian J Psychiatry</i>. 2010;52(4):371-372. doi:10.4103/0019-5545.74315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21267374/pubmed" id="21267374" target="_blank">21267374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12297603">
<a name="12297603"></a>Shahzad S, Suleman MI, Shahab H, et al. Cataract occurrence with antipsychotic drugs. <i>Psychosomatics</i>. 2002;43(5):354-349. doi:10.1176/appi.psy.43.5.354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12297603/pubmed" id="12297603" target="_blank">12297603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shelton.1">
<a name="Shelton.1"></a>Shelton RC, Bobo WV. Bipolar major depression in adults: Choosing treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21645873">
<a name="21645873"></a>Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597. doi:10.1016/j.sleep.2010.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/21645873/pubmed" id="21645873" target="_blank">21645873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16904298">
<a name="16904298"></a>Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. <i>Eur Neuropsychopharmacol</i>. 2007;17(2):79-93. doi:10.1016/j.euroneuro.2006.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16904298/pubmed" id="16904298" target="_blank">16904298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119438">
<a name="35119438"></a>Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. <i>Pediatr Crit Care Med</i>. 2022;23(2):e74-e110. doi:10.1097/PCC.0000000000002873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/35119438/pubmed" id="35119438" target="_blank">35119438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169. doi:10.1055/s-2007-971169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15039480">
<a name="15039480"></a>Sokolski KN, Brown BJ, Melden M. Urinary retention following repeated high-dose quetiapine. <i>Ann Pharmacother</i>. 2004;38(5):899-900. doi:10.1345/aph.1D502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15039480/pubmed" id="15039480" target="_blank">15039480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2018">
<a name="Stein.2018"></a>Stein M. Pharmacotherapy for posttraumatic stress disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 11, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096514">
<a name="16096514"></a>Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. <i>Int Clin Psychopharmacol</i>. 2005;20(5):243-251. doi:10.1097/01.yic.0000166405.49473.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16096514/pubmed" id="16096514" target="_blank">16096514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2018">
<a name="Stovall.2018"></a>Stovall J. Bipolar disorder in adults: choosing pharmacotherapy for acute mania and hypomania. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 10, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: Maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suh.2018">
<a name="Suh.2018"></a>Suh KN, Keystone JS. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12418358">
<a name="12418358"></a>Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? <i>Psychiatr Q</i>. 2002;73(4):297-311. doi:10.1023/a:1020464017021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/12418358/pubmed" id="12418358" target="_blank">12418358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28784372">
<a name="28784372"></a>Tay JL. Quetiapine causing severe fall and skull fracture-A case report. <i>Asian J Psychiatr</i>. 2017;28:150-151. doi:10.1016/j.ajp.2017.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28784372/pubmed" id="28784372" target="_blank">28784372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23485955">
<a name="23485955"></a>Thase ME, Montgomery S, Papakostas GI, et al. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.<i> Int Clin Psychopharmacol. </i>2013;28(3):113-120. doi:10.1097/YIC.0b013e32835fb971<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23485955/pubmed" id="23485955" target="_blank">23485955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thase.2018">
<a name="Thase.2018"></a>Thase M, Connolly KR. Unipolar depression in adults: Management of highly resistant (refractory) depression. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35933475">
<a name="35933475"></a>Thielen JR, Sawyer JE, Henry BM, Zebracki J, Cooper DS, Koh W. Short-term effect of quetiapine used to treat delirium symptoms on opioid and benzodiazepine requirements in the pediatric cardiac intensive care unit. <i>Pediatr Cardiol</i>. 2022. doi:10.1007/s00246-022-02980-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/35933475/pubmed" id="35933475" target="_blank">35933475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10958148">
<a name="10958148"></a>Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2000;24(4):521-533. doi:10.1016/s0278-5846(00)00090-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10958148/pubmed" id="10958148" target="_blank">10958148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.2019">
<a name="Tietze.2019"></a>Tietze K, Fuchs B. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2013 Nov;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2014 Nov;7(6):981]. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3, pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34426483">
<a name="34426483"></a>Torroba Sanz B, Mendez Martínez E, Cacho Asenjo E, Aquerreta Gonzalez I. Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine. <i>Eur J Hosp Pharm</i>. 2021;28(5):285-288. doi:10.1136/ejhpharm-2019-002149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/34426483/pubmed" id="34426483" target="_blank">34426483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31214433">
<a name="31214433"></a>Traube C, Witcher R, Mendez-Rico E, Silver G. Quetiapine as treatment for delirium in critically ill children: a case series. <i>J Pediatr Intensive Care</i>. 2013;2(3):121-126. doi:10.3233/PIC-13060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31214433/pubmed" id="31214433" target="_blank">31214433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27028982">
<a name="27028982"></a>Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252. doi:10.1097/JCP.0000000000000491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27028982/pubmed" id="27028982" target="_blank">27028982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15617511">
<a name="15617511"></a>Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <i>Am J Psychiatry</i>. 2004;161(11)(suppl):3-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/15617511/pubmed" id="15617511" target="_blank">15617511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.2017">
<a name="VADoD.2017"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf</a>. Updated June 2017. Accessed November 9, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11384916">
<a name="11384916"></a>Valibhai F, Phan NB, Still DJ, True J. Cataracts and quetiapine. <i>Am J Psychiatry</i>. 2001;158(6):966. doi:10.1176/appi.ajp.158.6.966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/11384916/pubmed" id="11384916" target="_blank">11384916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31342625">
<a name="31342625"></a>Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE. Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer's disease patients. <i>Geriatr Gerontol Int</i>. 2019;19(9):913-917. doi:10.1111/ggi.13748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/31342625/pubmed" id="31342625" target="_blank">31342625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30700975">
<a name="30700975"></a>Ventriglio A, Baldessarini RJ, Vitrani G, et al. Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics. <i>Front Psychiatry</i>. 2019;9:744. doi:10.3389/fpsyt.2018.00744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/30700975/pubmed" id="30700975" target="_blank">30700975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23497790">
<a name="23497790"></a>Vieta E, Bauer M, Montgomery S, et al. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. <i>J Affect Disord</i>. 2013;150(2):639-643. doi:10.1016/j.jad.2013.01.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23497790/pubmed" id="23497790" target="_blank">23497790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16156840">
<a name="16156840"></a>Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. <i>Acta Psychiatr Scand</i>. 2005;112(4):318-322. doi:10.1111/j.1600-0447.2005.00592.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/16156840/pubmed" id="16156840" target="_blank">16156840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418378">
<a name="27418378"></a>Villarreal G, Hamner MB, Cañive JM, et al. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. <i>Am J Psychiatry</i>. 2016;173(12):1205-1212. doi:10.1176/appi.ajp.2016.15070967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27418378/pubmed" id="27418378" target="_blank">27418378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24919175">
<a name="24919175"></a>Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. <i>Braz J Med Biol Res</i>. 2014;47(7):605-616. doi:10.1590/1414-431x20143672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/24919175/pubmed" id="24919175" target="_blank">24919175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19694628">
<a name="19694628"></a>Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. <i>Acta Psychiatr Scand</i>. 2010;121(3):190-200. doi:10.1111/j.1600-0447.2009.01464.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19694628/pubmed" id="19694628" target="_blank">19694628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord.</i> 2018;20(2):97-170. doi:10.1111/bdi.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol.</i> 2009;114(3):703-713. doi:10.1097/AOG.0b013e3181ba0632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32036034">
<a name="32036034"></a>Zenno A, Leschek E. Quetiapine-induced central hypothyroidism. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(5):575-576. doi:10.1016/j.jaac.2020.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/32036034/pubmed" id="32036034" target="_blank">32036034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17316169">
<a name="17316169"></a>Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia; a randomized, double-blind, placebo-controlled study. <i>Curr Alzheimer Res</i>. 2007;4(1)81-93. doi:10.2174/156720507779939805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/17316169/pubmed" id="17316169" target="_blank">17316169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: A systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quetiapine-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9570 Version 738.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
